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 SUMMARY 
Nanomaterials are appealing and valuable in various fields, 
as they are engineered to achieve particular physicochemical 
properties that are specific for their application. The present study was 
thus conducted in view of the mounting usage of silver nanoparticles 
(AgNPs) despite little being known about its toxicity and potential 
impacts on human health. The most prevalent toxicity mechanism for 
AgNPs is oxidative stress. Multiple studies have found that AgNPs 
preferentially disrupt mitochondrial function, since mitochondria are 
major reactive oxygen species (ROS) producers. Hence, the first part 
of the study was carried out to examine the acute effects of AgNPs in 
SH-SY5Y human neuroblastoma mitochondria, and possibly rescue the 
AgNPs-induced mitochondrial dysfunction through the use of 
docosahexaenoic acid (DHA) and l-carnitine (LC). Results from various 
mitochondrial assays revealed that acute exposure of AgNPs to SH-
SY5Y cells caused mitochondrial dysfunction, in particular, disrupted 
mitochondrial membrane potential, and loss of both ATP and ADP, 
which could be rescued by co-supplementation with DHA and LC. 
AgNPs have also demonstrated pro-inflammatory properties, 
although it is unknown if AgNPs enhance the effects of pro-
inflammatory mediators, inhibit anti-inflammatory mediators, or both. 
Thus, the second part of the study was conducted to examine the 
relationship between AgNPs and phospholipase A2 (PLA2) enzymes, in 
particular cPLA2 and iPLA2, in SH-SY5Y cells. Real-time RT-PCR and 
 Summary  
XI 
immunocytochemistry analyses revealed that iPLA2 expression, but not 
cPLA2, was altered following acute exposure to AgNPs. Interestingly, 
co-treatment of DHA and/or LC with AgNPs did not result in significant 
changes in iPLA2 gene expression, suggesting that AgNPs affect iPLA2 
expression upstream that of its effects exerted on mitochondria, 
explaining for the inability of DHA and/or LC to alter iPLA2 expression. 
Lipidomic analysis also revealed decreased iPLA2 activity after acute 
exposure to AgNPs.  
AgNPs have been reported to produce ROS in various cell 
lines, although it has not been determined if AgNPs-induced ROS 
exerts its effects on the inflammatory mediators. Therefore, the third 
part of the study was conducted to investigate the effects of AgNPs-
induced ROS on iPLA2 and to potentially elucidate the mechanism 
underlying changes observed. Antioxidant pre-treatment prevented the 
observed decrease in iPLA2 gene expression following AgNPs 
exposure, indicating that the AgNPs-induced down-regulation of iPLA2 
gene involves ROS. Since the iPLA2 promoter contains a sterol 
regulatory element (SRE) binding site for sterol regulatory element-
binding proteins (SREBPs) that is not found on cPLA2, the effect of 
oxidative stress on SREBP expression was investigated. Real-time RT-
PCR analyses suggest that SREBPs are affected by AgNPs-induced 
ROS formation. 
Taken together, the present study’s results indicate that 
AgNPs exposure results in ROS formation causing a down-regulation 
 Summary  
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of SREBP expression. This potentially reduces the amount of SREBP 
transcription factors binding to iPLA2 promoter, leading to a decrease in 
iPLA2 expression and activity, and in turn resulting in mitochondrial 
dysfunction. 
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1. Nanotechnology and Its Applications 
1.1. Nanotechnology 
Nanoscience and nanotechnology are the understanding 
and utilization of materials at a nanoscale, with size ranging between 1 
and 100 nm, in a broad range of scientific fields including engineering, 
biology, and material sciences (United States National Nanotechnology 
Initiative, 2015). The nanotechnology concept was first introduced in 
1959 by physicist Richard Feynman. He described a process in which 
individual atoms and molecules could be manipulated and controlled 
(United States National Nanotechnology Initiative, 2015). However, 
modern nanotechnology only begun in the 1980s, after the arrival of the 
scanning tunneling microscope, an instrument that allowed the viewing 
and manipulation of materials in the nanoscale (Fahlman, 2007, United 
States National Nanotechnology Initiative, 2015). 
Nanotechnology can be broadly split into three divisions; 
nanomaterials – structures with at least one dimension smaller than 
100 nm, nanodevices – production of nanoscale devices, and 
nanotools – techniques to synthesize and characterize nanomaterials 
and nanodevices (Borm et al., 2006). Although nanotechnology is a 
relatively new field, it has grown rapidly and extensively across wide-
ranging industries including biomedical, cosmetic, environmental, and 
material applications (Taton et al., 2000, Cui et al., 2001, Asz et al., 
2006, Chakraborty et al., 2009, Bi et al., 2015, Ongaro et al., 2015, 
Project on Emerging Nanotechnologies, 2015). Nanotechnology has 
Section I 
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also brought about new multidisciplinary fields such as nanomedicine 
and nanobiotechnology (Moore, 2006, Amini et al., 2014). 
Nanotechnology promises benefits to society and the 
economy. Current treatments for nervous system disorders are often 
inadequate due to the presence of the blood brain barrier (BBB), which 
restricts the uptake of neurotherapeutics (Abbott and Romero, 1996, 
Roney et al., 2005, Martel, 2015). However, nanoneuromedicine could 
offer plausible solutions. Nanoparticles (NPs) would be efficient drug 
carriers as the crossing of the BBB depends solely on the 
physicochemical properties of NPs and not the drug characteristics. 
Furthermore, manipulation of NP surface confers features that promote 
BBB targeting or enhances its crossing of the BBB (Masserini, 2013). 
Chitosan NPs, poly(lactic-co-glycolic acid) (PLGA) NPs, and gelatin 
nanostructured lipid carriers are promising carriers for nose-to-brain 
drug delivery (Seju et al., 2011, Md et al., 2014, Zhao et al., 2014b). 
Table 1.1.1 lists several NPs used as drug-delivery systems to the 
brain. Nanotherapeutics have also been used clinically, where some 
examples of FDA-approved drugs include Doxil (anti-cancer drug), 
Emend (anti-emetic drug), and AmBisome (anti-fungal drug) (Ventola, 
2012). Iron oxide NPs have also been studied as a potential contrast 
agent for bioimaging to gauge brain tumor progression (Neuwelt et al., 
2007, Gahramanov et al., 2011). Additionally, nanotechnology can 
improve the nature of food to meet the needs of a growing population. 
Crop quality and yield have been suggested to improve by using 
Section I 
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appropriate concentrations of fullerol, a carbon-based NP (Kole et al., 
2013). Carbon nanotubes (CNTs) are also commonly used to remove 
organic and inorganic pollutants from contaminated water (Li et al., 
2003b, Peng et al., 2005). The attractiveness of nanotechnology has 
thus brought about global multi-billion dollar investments (Guzman et 
al., 2006, Oberdörster et al., 2007). The Singapore government has 
also jumped onto the nanotechnology bandwagon, investing large 
amounts of money on research and development (Levine, 2014). 
Section I 
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Table 1.1.1 NPs as drug-delivery systems to the brain. 
Type of 
NP Surface modification Size (nm) Type of Drug Type of action Reference 
CBSA PEG 50 – 58 Aclarubicin Anti-cancer Lu et al. (2006) 
Chitosan Non-coated 15.23 Amyloid-β Vaccine Zhang and Wu (2009) 
PBCA Tween-80, PEG 20000 100 Hexapeptide dalargin Anti-nociceptive Das and Lin (2005) 
PBCA Polysorbate 80 41 Rivastigmine Anti-Alzheimer’s Wilson et al. (2008) 
PBCA Polysorbate 80 112 Gemcitabine Anti-cancer Wang et al. (2009) 
PLGA (R)-g7 143 – 197 Loperamide Opioid receptor agonist Tosi et al. (2007) 
PLGA Alginate hydrogel 400 – 600 Dexamethasone Anti-inflammatory Kim and Martin (2006) 




Zhao et al. (2014a) 
PLGA Glutathione 326.6 Triiodothyronine Thyroid hormone Mdzinarishvili et al. (2013) 
Tripalmitin Non-coated 358 – 362 Etoposide Anti-cancer Reddy et al. (2004) 
Section I 
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1.2. Nanomaterials 
Nanomaterials are defined as structures with at least one 
dimension smaller than 100 nm, where they can exist in various forms 
such as fibers, particles, tubes, and wires, of which NPs are considered 
the building blocks for nanomaterial production (Fahlman, 2007). They 
can be roughly categorized according to their chemical structures, such 
as metals (e.g. copper NPs), metal oxides (e.g. titanium dioxide (TiO2) 
NPs), carbon-based (e.g. CNTs), and hybrid structures (e.g. quantum 
dots) (Handy et al., 2008, Smita et al., 2012). Nanomaterials are 
engineered to achieve particular physicochemical properties that are 
specific for product application. At the nanoscale, matters display 
unusual biological, chemical, and physical properties unique from that 
of bulk materials (Smita et al., 2012, United States National 
Nanotechnology Initiative, 2015). The reduction in size results in large 
surface area to volume ratio, rendering elevated reactivity with 
surrounding surfaces (Fahlman, 2007, Christian et al., 2008, Smita et 
al., 2012). Changes to nanomaterial’s size or structure also result in 
alterations in fundamental properties, including improved strength, 
advanced optical characteristics, augmented chemical reactivity, and 
enhanced thermal or electrical conductivity (Fahlman, 2007, Singh et 
al., 2009, United States National Nanotechnology Initiative, 2015). 
These novel features enable nanomaterials to become appealing and 
valuable in various fields. In the biomedical field, nanomaterials are 
highly favored for utilization in drug delivery and/or targeting, especially 
Section I 
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due to their ability to carry an array of drugs and be targeted to specific 
organs through manipulation of surface features (Hans and Lowman, 
2002, Chouhan and Bajpai, 2009). For instance, rivastigmine is 
delivered to the brain for treatment of Alzheimer’s disease via poly(n-
butylcyanoacrylate) (PBCA) NPs coated with polysorbate 80 (Wilson et 
al., 2008). Commercially, there are close to 2,000 nanoproducts (Fig. 
1.1.1) of which majority is made up of health and fitness related 
products, such as cosmetics, sporting goods, and clothing (Fig. 1.1.2) 
(Project on Emerging Nanotechnologies, 2015). Researchers are also 
exploring potentials of nanomaterials in scientific and technical areas 
such as biomaterials, clinical diagnosis, and tissue engineering (Basu 
et al., 2004, Stuart et al., 2006, Wang et al., 2014b). 
 
           
Fig. 1.1.1 Nanoproducts that are currently commercially available. 
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Fig. 1.1.2 Health and fitness nanoproducts that are currently 
commercially available. Adapted from Project on Emerging 
Nanotechnologies (2015). 
 
However, these unique properties of nanomaterials could 
also result in potential health and environmental hazards (Guzman et 
al., 2006, Oberdörster et al., 2007). In vitro and in vivo tests have 
revealed adverse effects of nanomaterials. Nanomaterials have been 
reported to cause oxidative stress, genotoxicity, and cytotoxicity 
(Hussain et al., 2005, Li et al., 2008, Nalika and Parvez, 2015). 
Oxidative stress occurs when the antioxidant defenses in cells are 
unable to overcome reactive oxygen species (ROS) production 
(Halliwell, 1996), leading to a range of adverse biological 
consequences. Nanomaterials induce ROS generation in different 
manners including its inherent characteristics such as size and 
composition, and through interactions with cellular components like 
















Health & Fitness Subcategories!
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mitochondrial dysfunction, and cell death (Li et al., 2008, Sohaebuddin 
et al., 2010, Chairuangkitti et al., 2013, Manke et al., 2013). 
Nanomaterials preferentially localize in mitochondria (Foley et al., 
2002, Li et al., 2003a), and its deposition could disrupt mitochondrial 
functions by affecting the electron transport chain (ETC), leading to the 
formation of ROS and reduced adenosine triphosphate (ATP) 
production (Arora et al., 2008, AshaRani et al., 2009). Nanomaterials 
can also enter the bloodstream via multiple routes of exposure 
including dermal, inhalation, and oral (Table 1.1.2). They then circulate 
throughout the body, and are taken up by tissues and organs. Over 
time, it could lead to nanomaterial accumulation in organs, resulting in 
harmful effects such as tissue dysfunction and inflammation. Generally, 
nanomaterial biodistribution is size-dependent. Smaller nanomaterials 
tend to distribute to more organs, exhibit greater accumulation, and 
induce stronger toxicities than larger nanomaterials (Balasubramanian 
et al., 2013).  
Section I 
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Table 1.1.2 Effects of NPs via various exposure routes in different organisms. 
Organism NP Size (nm) Exposure route Affected organs Comments Reference 
Sprague-
Dawley rat 





Sung et al. (2009) 
Hartley albino 
guinea pig 
AgNPs < 100 Dermal Skin, liver, spleen Histopathologic 
anomalies 
Korani et al. (2011) 







et al. (2010) 
Athymic nude 
mouse 






Low retention in RES, 
rapid clearance 
through kidneys 
Huang et al. (2013) 
CD-1 mouse Ceria NPs Not 
reported 
Oral Liver, lungs, blood Inflammation Poma et al. (2014) 
Wistar rat Manganese 
oxide NM 




Singh et al. (2013) 
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Nanomaterials could also be released into the environment 
during the production process and its subsequent use, leading to 
ecotoxicity. For instance, silver NPs (AgNPs) have been found to leach 
from commercially available products (Benn and Westerhoff, 2008, 
Kaegi et al., 2010, Farkas et al., 2011). Discharged nanomaterials may 
interact with the environment resulting in alterations in its 
physicochemical characteristics, potentially modifying its toxicity profile 
(Lyon et al., 2005, Klaine et al., 2008). Organisms, including 
microorganisms, will then take up the released nanomaterials in the 
ecosystem. Presence of CNTs and TiO2 NPs in the living environment 
of rainbow trout has led to organ pathologies, biochemical effects, and 
respiratory problems (Federici et al., 2007, Smith et al., 2007). 
Nanomaterials have also shown to be toxic to microbes (Sondi and 
Salopek-Sondi, 2004, Lyon et al., 2005, Adams et al., 2006), which is 
critical as microorganisms form the foundation of both aquatic and 
terrestrial ecosystems (Jafar and Hamzeh, 2013). 
 
1.2.1. Gold Nanomaterials 
Gold NPs (AuNPs) have been used in various consumer 
products including cosmetics, food and beverage, and electronic 
appliances (Project on Emerging Nanotechnologies, 2015). It is also 
commonly employed in the development of biomedical applications 
such as cancer diagnostics and therapeutics (El-Sayed et al., 2006, 
Huff et al., 2007, Ojeda et al., 2007, Parry et al., 2013), treatment for 
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rheumatoid arthritis (Tsai et al., 2007, Lee et al., 2013), and cell 
imaging (Chen et al., 2005, Shukla et al., 2005b). AuNPs are thought to 
be safe as bulk gold is chemically inert. This allows the manipulation of 
AuNPs’ size and shape without compromising its stability and toxicity 
profiles (Zhang, 2015). It has been established that AuNPs enter living 
cells through endocytosis (Shukla et al., 2005a), with several studies 
demonstrating that AuNPs are normally retained in endosomes 
(Goodman et al., 2004, Chithrani et al., 2006). 
Conflicting reports of AuNPs’ toxicity exists. It has been 
suggested that cytotoxicity of AuNPs is largely dependent on its 
physical features and cell lines. Several in vitro and in vivo studies 
have demonstrated that AuNPs do not show overt toxicity. Despite 
being taken up into human K562 cells, AuNPs did not cause acute 
cytotoxicity (Connor et al., 2005). Additionally, there was no inhibition in 
proliferation of normal peripheral blood mononuclear cells, while the 
proliferation of three multiple myeloma cell lines were significantly 
inhibited following AuNPs exposure (Bhattacharya et al., 2007). When 
exposed to zebrafish embryos (Bar-Ilan et al., 2009, Asharani et al., 
2011) and mice (Zhang et al., 2010), AuNPs also did not exhibit 
significant cytotoxicity. Interestingly, Avalos et al. (2015) did not find 
consistent changes in cytotoxicity in response to differences in AuNPs 
size, however, Pan et al. (2007) found that 1 to 2 nm AuNPs were 
highly toxic, while larger AuNPs, of up to 15 nm, were non-toxic in four 
representative cell lines. On the other hand, Mironava et al. (2010) 
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determined that larger AuNPs led to major damage in human dermal 
fibroblasts. Similarly, AuNPs with cationic side chains were determined 
to be moderately toxic while anionic particles were nontoxic (Goodman 
et al., 2004). AuNPs may also be identified as foreign materials by 
immune cells resulting in acute inflammation and apoptosis (Cho et al., 
2009).  
Although AuNPs are usually associated with low or no 
significant cell death, AuNPs may cause serious cellular damage. 
AuNPs promoted abnormal actin fiber formation in human dermal 
fibroblasts, leading to decreased cell proliferation, adhesion, and 
motility (Pernodet et al., 2006). AuNPs could also trigger stress 
response pathways in cells, including activation of stress-specific 
kinases, glutathione transferase activities, and chaperone induction 
(Khan et al., 2007). Multiple studies have reported elevated intracellular 
ROS levels in response to AuNPs exposure (Taggart et al., 2014). 
Additionally, Khan et al. (2007) observed activation of more than 30 
genes upon AuNPs exposure, indicating that unaffected cell viability 
does not equate to absence of cellular processes alterations. 
 
1.2.2. Silver Nanomaterials 
Silver has been known for its disinfectant properties for 
centuries. Silver powder was documented as ulcer treatment, while 
silver-containing cream is still used for serious burn wounds (Chen and 
Schluesener, 2008). Similarly, AgNPs have been established as 
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effective biocides against bacteria, fungi, and virii (Elechiguerra et al., 
2005, Hernandez-Sierra et al., 2008, Kim et al., 2009a, Marambio-
Jones and Hoek, 2010). Due to their innate strong antibacterial 
characteristic, AgNPs have been utilized in many daily commercial 
products including cosmetics, kitchenware and textiles. They are also 
frequently used in medical applications such as wound dressings and 
antibacterial coatings of medical instruments (Asz et al., 2006, Lee et 
al., 2007, Eby et al., 2009, Project on Emerging Nanotechnologies, 
2015). As such, AgNPs are said to be the most frequently utilized 
nanomaterial in consumer products (Chen and Schluesener, 2008, 
Beer et al., 2012), making up approximately 24 % of all nanoproducts 
(Project on Emerging Nanotechnologies, 2015). 
Despite its popularity, severe human health considerations 
have been brought up. AgNPs can reach the brain in a variety of ways. 
Inhalation of AgNPs allows AgNPs to reach the olfactory bulb and brain 
via traveling across the upper respiratory tract (Takenaka et al., 2001, 
Ji et al., 2007, Sung et al., 2009). AgNPs can also cross the BBB and 
damage its integrity (Tang et al., 2009, Sharma et al., 2010, Trickler et 
al., 2010), exposing the brain to previously restricted elements, such as 
immunological mediators and neurodestructive factors, leading to 
abnormal cellular reactions and injuries (Sharma et al., 2010). The 
most common mechanism of toxicity for AgNPs is oxidative stress. 
Exposure to AgNPs results in elevated ROS production, depletion of 
glutathione, and reduced superoxide dismutase activity (Hussain et al., 
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2005, Arora et al., 2008, Hsin et al., 2008, Kim et al., 2009b, Mukherjee 
et al., 2012). Additionally, exposure to AgNPs led to obvious alterations 
in expression of stress response genes involved in oxidative stress, 
endoplasmic reticulum stress, and apoptosis in an in vitro human 
intestine model (Bouwmeester et al., 2011). Multiple studies have 
found that AgNPs preferentially disrupt mitochondrial function 
(AshaRani et al., 2009, Costa et al., 2010, Kang et al., 2012, 
Mukherjee et al., 2012, Stensberg et al., 2013), since mitochondria are 
major sites of ROS production. Excessive formation of ROS can result 
in mitochondrial damage, in turn leading to uncontrolled ROS 
generation (Guo et al., 2013). Apart from mitochondria, AgNPs also 
exert genotoxic effects in cells. The generation of ROS from AgNPs 
exposure causes spontaneous DNA damage, alterations to cell cycle, 
and ultimately cell death (Cooke et al., 2003, AshaRani et al., 2009, 
Kim et al., 2009b, Eom and Choi, 2010, Guo et al., 2013). 
Exposure of animals to AgNPs also resulted in inflammatory 
responses. A single intratracheal instillation of AgNPs in rats resulted in 
distinct inflammatory responses across 28 days (Park et al., 2011). 
Additionally, a microarray analysis of mice liver RNA revealed 
alterations in expression of genes involved in apoptosis and 
inflammation that resulted in phenotypical changes following exposure 
to AgNPs (Cha et al., 2008). Similarly, rats exposed to AgNPs showed 
changes in expression of proteins that moderate ROS formation, 
inflammation and apoptosis (Kim et al., 2010).  
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2. Mitochondria and Its Related Compounds 
2.1. Mitochondria 
Mitochondria are commonly known as cellular powerhouses 
(Correia et al., 2010, Marchi et al., 2012). Apart from the generation of 
ATP, mitochondria are involved in other essential functions in cells, 
such as cell cycle regulation, differentiation, calcium homeostasis, and 
cell death (Raimundo, 2014). 
Mitochondrion is made up of an outer and inner membrane 
enclosing a matrix space, which contains enzymes that are involved in 
terminal catabolic pathways, such as the citric acid cycle (Schaffer and 
Suleiman, 2007, Alberts et al., 2008). The inner mitochondrial 
membrane is a specialized convoluted phospholipid membrane that 
contains a series of enzymes, known as the ETC. ETC uses electrons 
to translocate protons across the inner mitochondrial membrane 
generating an electrochemical gradient, which makes up the 
mitochondrial membrane potential, for the reformation of ATP (Fig. 
1.2.1) (Leuner et al., 2007, Schaffer and Suleiman, 2007, Alberts et al., 
2008, Keane et al., 2011, Marchi et al., 2012, Voet et al., 2013). This 
process is known as oxidative phosphorylation, and accounts for 95 % 
of energy required by brain (Chang and Reynolds, 2006). ATP is 
transported out of mitochondria via adenine nucleotide translocase 
(ANT) for use in various parts of the cell, and in the process is 
hydrolyzed back to adenosine diphosphate (ADP) and inorganic 
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phosphate (Pi) (Duchen, 2004, Ballinger, 2005, Alberts et al., 2008, 
Voet et al., 2013). 
 
 
Fig. 1.2.1 Schematic diagram of the ETC. Electrons are transferred 
across mitochondrial complexes I to IV, resulting in the corresponding 
pumping of H+ from the matrix (low concentration of H+) to 
intermembrane space (high concentration of H+), across the inner 
mitochondrial membrane. This electrochemical gradient is used for the 
reformation of ATP from ADP and Pi, via ATP synthase. Dotted red 
lines denote movement of H+, while dotted purple lines denote 
movement of electrons (e-). Abbreviations: Cyt C: cytochrome C; e-: 
electrons; H+: hydrogen ions; I – IV: mitochondrial complexes I to IV; Q: 
coenzyme Q. Adapted from Keane et al. (2011). 
 
As a consequence to being the leading energy producer in 
cells, mitochondria are primary sites of ROS generation (AshaRani et 
al., 2009, Marchi et al., 2012). Electrons readily interact with oxygen 
during the oxidative phosphorylation process producing ROS, which 
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then interact with DNA, lipids, and proteins leading to oxidative damage 
(Marchi et al., 2012). Mitochondria destroy ROS using endogenous 
antioxidants such as vitamin E, coenzyme Q and glutathione, or 
enzymatically through activation of superoxide dismutase and catalase. 
However, when the antioxidant defenses cannot keep up with the 
production of ROS, ROS would accumulate in mitochondria 
(Mukhopadhyay and Weiner, 2007). Mitochondria are major targets of 
ROS as mitochondrial DNA, lipids, and proteins are susceptible to 
oxidative damage (Leuner et al., 2007, Pieczenik and Neustadt, 2007, 
Marchi et al., 2012). Additionally, mitochondria play crucial roles in cell 
death where the breakage of the outer mitochondrial membrane via the 
opening of mitochondrial permeability transition pore (MPTP) and the 
dissipation of the electrochemical gradient could result in apoptosis 
and/or necrosis (Kroemer et al., 1998, Green and Kroemer, 2004, 
Orrenius, 2004, Montero et al., 2010). Mitochondrial dysfunction has 
been associated with pathological development of various chronic 
neurodegenerative disorders, such as amyotrophic lateral sclerosis, 
Alzheimer’s disease, and Parkinson’s disease (Cozzolino et al., 2015, 
Ferrigno et al., 2015, Long et al., 2015). 
 
2.2. Docosahexaenoic Acid 
Docosahexaenoic acid (DHA, 22:6) (Fig. 1.2.2), a long-chain 
polyunsaturated fatty acid (PUFA), is the most abundant fatty acid in 
brain and is a structural component of neuronal membranes (Horrocks 
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and Farooqui, 2004). However, neurons do not have the capability to 
produce DHA. Instead, it is taken up through the diet, and subsequently 
transported across the BBB and inserted into the sn-2 position of 
glycerol backbone of membrane phospholipids (Glomset, 2006, Lukiw 
and Bazan, 2008, Nguyen et al., 2014). Due to its high number of 
double bonds, DHA helps to increase membrane fluidity, hence 
moderating membrane organization and function (Yang et al., 2011). 
Supplementation of DHA in HL-60 and Neuro-2A cells led to its 
incorporation into neural cell membranes, resulting in increased 
resistance against excitotoxic damage (Horrocks and Farooqui, 2004). 
High intake of DHA also resulted in its incorporation into mitochondrial 
membrane phospholipids, and was coupled to a resistance to Ca2+-
induced MPTP opening (O'Shea et al., 2009, Khairallah et al., 2010, 
Khairallah et al., 2012).  
DHA is crucial in neuroprotection as it contains anti-oxidative 
stress, anti-inflammation, and anti-apoptotic properties (Eady et al., 
2012, Tanaka et al., 2012). However, as the most common PUFA, 
DHA is a target for lipid peroxidation (Stillwell et al., 1997). Prolonged 
oxidative stress can oxidize DHA into prostaglandin-like substances, 
triggering the production of ROS leading to further oxidative stress, a 
vicious cycle that will result in extensive damage (Porter et al., 1995, 
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Fig. 1.2.2 Structure of DHA. Adapted from Rajnavolgyi et al. (2014). 
 
2.3. L-Carnitine 
L-carnitine (LC) (Fig. 1.2.3) is an endogenous compound 
found in all mammalian species, which exists mainly as the unesterified 
form (Walter and Schaffhauser, 2000, Jones et al., 2010). It can be 
transported and accumulated in brain (Bresolin et al., 1982, Jones et 
al., 2010). LC is essential for brain function, where the absence of LC 
results in major detrimental consequences in brain, such as 
development of metabolic encephalopathy (Kimura and Amemiya, 
1990, Jones et al., 2010). 
The main function of LC is to facilitate fatty acid transport 
into mitochondrial matrix for the production of ATP via β-oxidation 
(Kerner and Hoppel, 2000, Walter and Schaffhauser, 2000, Hoppel, 
2003). This occurs via a three-step process known as the carnitine 
shuttle (Fig. 1.2.4). Acyl-CoA found in the cytosol is transferred onto LC 
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transported into mitochondrial matrix for β-oxidation (Virmani and 
Binienda, 2004, Sharma and Black, 2009, Houten and Wanders, 2010). 
The carnitine shuttle is critical as elevated levels of free fatty acids can 
result in mitochondrial dysfunction such as membrane damage, leading 
to mitochondria-dependent cell death (Virmani et al., 1995, Luo et al., 
1999, Furuno et al., 2001, Sharma and Black, 2009). LC effectively 
protects mitochondria and cells against oxidative stress by inhibiting 
mitochondrial membrane depolarization and ROS formation, increasing 
mitochondrial functions, and preventing cell death in serum- or glucose-
deprived medium (Ishii et al., 2000, Virmani and Binienda, 2004, Hino 
et al., 2005, He et al., 2011, Geier and Geier, 2013). Additionally, LC 
actively scavenges for ROS, playing a potential antioxidant role in cells 
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Fig. 1.2.4 Schematic diagram of the carnitine shuttle. CPT-1 transfers 
an acyl-CoA onto carnitine to form acyl-carnitine, which is then 
translocated across the inner mitochondrial membrane via CACT. In 
the mitochondrial matrix, CPT-2 catalyzes the conversion of acyl-
carnitine back to acyl-CoA and carnitine, where acyl-CoA can then 
undergo β-oxidation. Carnitine is then brought out from mitochondria 
via CACT. Dotted black lines denote movement of various compounds. 
Abbreviations: CACT: carnitine-acylcarnitine translocase; CPT-1: 
carnitine palmitoyltransferase-1; CPT-2: carnitine palmitoyltransferase-
2. Adapted from Sharma and Black (2009). 
 
3. Phospholipase A2 
3.1. Phospholipase A2 
Phospholipase A2 (PLA2) is a superfamily of enzymes that 
cleaves the acyl ester bond of glycerophospholipids at the sn-2 
position, in turn releasing free fatty acids and lysophosholipids (Dennis, 
1994, Takenaka et al., 2001, Burke and Dennis, 2009, Ong et al., 
2015). Almost 20 PLA2 enzymes have been identified (Kudo, 2004, 
Sun et al., 2014) based on structural and biochemical features 
including sequence similarity and subcellular localization (Dennis, 
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1997, Tang et al., 1997). These enzymes have been grouped into 
several broad families such as calcium-independent PLA2 (iPLA2), 
cytosolic PLA2 (cPLA2), and secretory PLA2 (sPLA2), which are then 
subdivided further into various isoforms (Dennis, 1994, Farooqui et al., 
1997, Sun et al., 2004, Ong et al., 2015). 
PLA2s play many integral roles in brain such as modulating 
neurotransmitter release, long-term potentiation (LTP), and behavioral 
and cognitive functions, and are crucial for signal transduction, 
production of eicosanoids and lipid mediators, inflammation, membrane 
remodeling, and lipid metabolism (Dennis, 1997, Farooqui et al., 1997, 
Farooqui et al., 2000, Farooqui et al., 2006, Schaloske and Dennis, 
2006, Ong et al., 2010, Murakami et al., 2011, Sun et al., 2014). These 
enzymes work as critical regulators of cell membrane phospholipids via 
the deacylation-reacylation cycle, by working as the initiation point of 
activation, releasing fatty acids and lysophospholipids (Fig. 1.2.5) (Sun 
and MacQuarrie, 1989, Sun et al., 2014). Under normal conditions, 
PLA2s maintain structure and function of membranes via removing 
oxidized fatty acids from phospholipids, hence preventing membrane 
lipid peroxidation (Tan et al., 1984, Sevanian and Kim, 1985, McLean 
et al., 1993, Ong et al., 2015). In pathological conditions however, 
elevated activation of PLA2 enzymes results in increased production of 
fatty acids and lysophospholipids that will be metabolized to form 
second messengers and metabolites that could lead to alterations in 
membrane permeability, stimulation of lipolytic enzymes, and 
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inflammation (Sun et al., 2005, Sun et al., 2014, Ong et al., 2015). 
Hence, PLA2 enzymes are said to be major components involved in 
oxidative stress and inflammation in brain, and have been implicated in 
a range of neurological disorders (Farooqui et al., 1997, Liu and Xu, 
2010, Ong et al., 2015). 
 
 
Fig. 1.2.5 Schematic diagram of the PLA2 enzymatic pathway. PLA2 
acts on cell membrane phospholipids, releasing fatty acids and 
lysophospholipids, which can be further metabolized to form second 
messengers and metabolites. Abbreviations: AA: arachidonic acid; 
COX: cyclooxygenases; DHA: docosahexaenoic acid; LOX: 
lipoxygenases; LysoPC: lysophosphatidylcholine; LysoPE: 
lysophosphatidylethanolamine; PLA2: phospholipase A2. 
 
3.2. Secretory Phospholipase A2 
sPLA2 enzymes have low molecular weights of 14 – 19 kDa, 
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IIE, sPLA2-IIF, sPLA2-III, sPLA2-V, sPLA2-X, sPLA2-XIIA, and sPLA2-
XIIB (Kudo and Murakami, 2002). In the rat brain, sPLA2 isoforms are 
found in all regions, with highest activities in medulla oblongata, pons, 
and hippocampus, and lowest in olfactory bulb and cerebellum (Thwin 
et al., 2003). It is synthesized intracellularly, and in its mature form is 
secreted from the cytoplasm to the extracellular space to exert its 
effects on glycerophospholipids (Gentile et al., 2012, Sivaprakasam 
and Nachiappan, 2015).  
sPLA2 is dependent on Ca2+ for its functions, and lacks 
specificity for cleavage of fatty acids at the sn-2 position of 
glycerophospholipids (Murakami and Kudo, 2002, Sun et al., 2004, 
Schaloske and Dennis, 2006, Burke and Dennis, 2009, Yagami et al., 
2014, Ong et al., 2015). sPLA2 has been shown to release arachidonic 
acid (AA), oleic acid, and linoleic acid, as well as other pro-
inflammatory mediators from glycerophospholipids (Rosengren et al., 
2006). sPLA2-IIA, sPLA2-V, and sPLA2-X have been reported to amplify 
eicosanoid production by either modulating cPLA2 activity or directly 
releasing AA (Han et al., 2003, Kikawada et al., 2007). Studies reveal 
that pro-inflammatory cytokines and lipopolysaccharides induce sPLA2 
mRNA expression (Li et al., 1999, Shen et al., 2005, Sun et al., 2007). 
sPLA2 activity has been recorded in various inflammatory conditions 
such as sepsis, arthritis, acute lung injury, and neutrophilic 
inflammation (Suzuki et al., 2000, Munoz et al., 2009, Boilard et al., 
2010). Elevated gene and protein expressions of sPLA2 have also 
Section I 
 Introduction	   	  
26 
been reported in neurodegenerative diseases including Alzheimer’s 
disease (Moses et al., 2006), cerebral ischemia (Lin et al., 2004), and 
multiple sclerosis (Cunningham et al., 2006).  
Apart from its PLA2 activity, sPLA2 is involved in the release 
of neurotransmitters (Matsuzawa et al., 1996) and neurite outgrowth 
(Ikeno et al., 2005, Burke and Dennis, 2009). sPLA2 is also found in 
mitochondrial fractions, playing a role in the regulation of mitochondrial 
phospholipid composition and the proper functioning of the ETC 
(Zhang et al., 1999, Adibhatla et al., 2003, Gentile et al., 2012). 
 
3.3. Cytosolic Phospholipase A2 
cPLA2 enzymes have high molecular weights of 85 – 110 
kDa, and consist of cPLA2α, cPLA2β, cPLA2γ, cPLA2δ, cPLA2ε, and 
cPLA2ζ (Molloy et al., 1998, Balboa et al., 2002). In normal rats, basal 
mRNA expression of cPLA2 is kept very low in brain (Pardue et al., 
2003). cPLA2 protein is found uniformly across various regions of rat 
brain, with relatively high levels of expression in hypothalamus, 
brainstem, cerebellum, and spinal cord (Ong et al., 1999).  
cPLA2 requires Ca2+ for its activities and preferentially 
releases AA from glycerophospholipids (Murakami and Kudo, 2002, 
Sun et al., 2004, Dennis et al., 2011, Murakami et al., 2011, Ong et al., 
2015). AA plays a critical role in multiple physiological functions. It 
serves as a substrate for cyclooxygenases (COX) and lipoxygenases 
(LOX) to become precursors for eicosanoids and prostanoids, which 
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mediate inflammatory responses in cells (Kramer and Sharp, 1997, 
Uozumi et al., 1997, Phillis et al., 2006, Calder, 2008, Farooqui, 2012, 
Sun et al., 2014). Discrepancies in eicosanoid production could lead to 
chronic inflammation, disturbing signaling pathways that could result in 
irregular immune functions (Harizi et al., 2008, Serhan, 2010). 
Additionally, cPLA2 can be activated by ROS (Xu et al., 2003, Zhu et 
al., 2006, Sun et al., 2007) and AA metabolism produces ROS as a by-
product (Gentile et al., 2012). Hence, elevated cPLA2 activity is often 
associated with oxidative stress and neuroinflammation (Arai et al., 
2001, Ong et al., 2003, Farooqui and Horrocks, 2006, Tanaka et al., 
2012). For instance, cPLA2 has been associated with a range of 
inflammatory neurological disorders including Alzheimer’s disease 
(Gentile et al., 2012, Sagy-Bross et al., 2014), Parkinson’s disease 
(Klivenyi et al., 1998), multiple sclerosis (Nomura et al., 2011, Yang et 
al., 2014), and spinal cord injury (Liu and Xu, 2010). It is therefore 
crucial to regulate activity of cPLA2 stringently so as to preserve 
appropriate levels of AA and lysophospholipases for cellular 
homeostasis (Katsuki and Okuda, 1995, Farooqui et al., 2006, Sun et 
al., 2010, Gentile et al., 2012). 
Although attention on cPLA2 is primarily due to its 
preference for AA release leading to inflammation, it is also involved in 
other functions in cells. Like other PLA2 enzymes, cPLA2 moderates 
membrane fluidity, and affect downstream signaling pathways via the 
action of released fatty acids, their metabolites, and lysophospholipids. 
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It also plays a role in regulation of membrane trafficking (San Pietro et 
al., 2009, Ha et al., 2012, Leslie, 2015), and synaptic plasticity via LTP 
and long-term depression (LTD) (Bazan, 2005, Le et al., 2010, Wang et 
al., 2014a, Leslie, 2015). Apart from its phospholipase activity, cPLA2 
exerts lysophospholipase and transacetylase activities although the 
physiological relevance is currently unknown (Ghosh et al., 2006, 
Dennis et al., 2011, Gentile et al., 2012, Leslie, 2015).  
 
3.4. Calcium-Independent Phospholipase A2 
iPLA2 has a molecular weight of 85 – 88 kDa, and exists as 
a multimeric complex (Ackermann et al., 1994, Tang et al., 1997, 
Winstead et al., 2000). Multiple splice variants have been discovered, 
including iPLA2α, iPLA2β, iPLA2γ, iPLA2δ, iPLA2ε, iPLA2ζ, and iPLA2η 
(Mancuso et al., 2000, Tanaka et al., 2000, Balboa et al., 2002, van 
Tienhoven et al., 2002, Jenkins et al., 2004, Glynn, 2005). iPLA2 is 
found in all regions of brain, with high expression in cerebral cortex, 
basal ganglia, brainstem, and cerebellum, and is localized in the 
cytoplasm (Ong et al., 2005).  
Unlike cPLA2 and sPLA2, iPLA2 has been postulated to show 
preference for DHA release at the sn-2 position of 
glycerophospholipids (Murakami and Kudo, 2002, Strokin et al., 2003, 
Farooqui and Horrocks, 2006, Strokin et al., 2007, Green et al., 2008, 
Basselin et al., 2010, Ong et al., 2015). Both DHA and its derivative 
neuroprotectin D1 (NPD1) have revealed neuroprotective roles in the 
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central nervous system (CNS) (Bazan et al., 2013). DHA is 
metabolized by 15-LOX enzyme to docosanoids such as resolvins and 
neuroprotectins, which antagonize effects of AA-derived pro-
inflammatory eicosanoids thus exhibiting anti-inflammatory and anti-
apoptotic characteristics (Hong et al., 2003, Mukherjee et al., 2004, 
Serhan, 2005, Bazan, 2009, Orr et al., 2013). Under conditions of 
oxidative stress and inflammation, NPD1 has been shown to up-
regulate anti-apoptotic proteins while down-regulating pro-apoptotic 
proteins, resulting in an overall pro-survival situation (Mukherjee et al., 
2004, Lukiw et al., 2005, Bazan, 2007). 
iPLA2 is an integral ‘housekeeping’ enzyme, highly 
expressed in brain under normal conditions (Ong et al., 2010). Similar 
to other PLA2 enzymes, iPLA2 is heavily involved with lipid regulation, 
cell signaling, and transcriptional regulation (Balsinde et al., 1997, 
Isenovic and LaPointe, 2000, Williams and Ford, 2001, Moran et al., 
2005, Hooks and Cummings, 2008). In the brain, iPLA2 has been 
associated with neurotransmitter release (St-Gelais et al., 2004), LTP 
and memory (Schaeffer and Gattaz, 2005, Shalini et al., 2014). The 
remodeling and repair of membrane phospholipids by iPLA2 could also 
protect mitochondrial integrity and function, since mitochondria are key 
ROS-generating organelles in cells. Seleznev et al. (2006) 
demonstrated a reduction in caspase-3 activation, fragmentation of 
DHA, and phosphatidylserine (PS) externalization upon iPLA2 
expression in INS-1 cells, preventing mitochondria-induced apoptosis. 
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Moreover, iPLA2 has been reported to repair oxidized mitochondrial 
membrane components, and modulate opening of MPTP (Gadd et al., 
2006, Zhao et al., 2010). Mutations in iPLA2 gene have been 
associated with development of neurologic childhood disorders due to 
iron accumulation in brain (Sun et al., 2010, Illingworth et al., 2014). 
Abnormal iPLA2 has also been observed in cerebellar atrophy, 
dystonia-parkinsonism, and increased expression of Lewy bodies and 
neurofibrillary tangles (Kurian et al., 2008, Paisan-Ruiz et al., 2009, 
Sun et al., 2010). 
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Table 1.1.3 Key characteristics of PLA2 isoforms. 
sPLA2 cPLA2 iPLA2 
14 – 19 kDa 85 – 110 kDa 85 – 88 kDa 
Synthesized intracellularly, with mature 
form secreted to extracellular space 
Requires Ca2+ for activities and 
preferentially releases AA 
Preference for DHA release 
Lacks specificity for cleavage of fatty 
acids 
Elevated cPLA2 activity often associated 
with oxidative stress and 
neuroinflammation 
Integral ‘housekeeping’ enzyme, highly 
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The introduction of nanotechnology in recent years has 
brought about multiple benefits to society and the economy, where 
novel features of nanomaterials enable them to become appealing and 
valuable in wide-ranging fields. AgNPs are said to be the most 
frequently utilized nanomaterial in consumer products (Chen and 
Schluesener, 2008, Beer et al., 2012), making up approximately 24 % 
of all nanoproducts (Project on Emerging Nanotechnologies, 2015). 
Much research has been conducted on the health effects of AgNPs 
with respect to organs such as the lungs and liver, however, little is 
known about the impacts on the human brain. Recent studies revealed 
the ability of AgNPs to readily cross the BBB, exerting its effects on the 
CNS (Tang et al., 2009, Sharma et al., 2010, Trickler et al., 2010). 
Additionally, multiple studies have found that AgNPs preferentially 
disrupt mitochondrial function (AshaRani et al., 2009, Costa et al., 
2010, Kang et al., 2012), since mitochondria are major sites of ROS 
production. Apart from disrupting mitochondrial function, nanotoxicity is 
often associated with the triggering of inflammatory responses (Park 
and Park, 2009, Xue et al., 2012, Panas et al., 2013). 
The present study was conducted in view of the mounting 
usage of AgNPs despite little being known about its toxicity and 
potential impacts on human and environmental health. Hence, several 
issues would be examined in this study. Firstly, the current study aims 
to investigate the effect of AgNPs on human neuronal mitochondria, as 
mitochondria are crucial organelles in cells (Raimundo, 2014), and 
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mitochondrial dysfunction often leads to cell death (Montero et al., 
2010). AgNPs have been reported to target mitochondria (AshaRani et 
al., 2009), although little is known about its effects in human neuronal 
cells. Additionally, I wanted to determine if any mitochondrial 
dysfunction observed could be rescued through the use of endogenous 
compounds, such as DHA and/or LC, since these compounds have 
shown to be essential for healthy mitochondrial function (He et al., 
2011, Khairallah et al., 2012).  
AgNPs have also demonstrated inflammatory properties 
(Kim et al., 2010). However, it is unknown if AgNPs enhances the 
effects of pro-inflammatory mediators, inhibit anti-inflammatory 
mediators, or both. Thus, the current study aimed to examine the effect 
of AgNPs on inflammatory mediators, in particular the pro-inflammatory 
mediator, cPLA2, and the anti-inflammatory mediator, iPLA2. 
Furthermore, AgNPs have been reported to produce ROS in various 
cell lines (Mukherjee et al., 2012), although it has not been determined 
if AgNPs-induced ROS exerts its effects on the inflammatory 
mediators. Hence, aims 4 and 5 of the present study were to 
investigate effects of AgNPs-induced ROS on inflammatory mediators 
and to elucidate the mechanism underlying changes observed. 
Due to the increasing usage of AgNPs in consumer 
products, it is crucial to highlight and understand the potential toxicities 
of AgNPs on human health. It is hoped that the present study could 
provide additional insights with respect to AgNPs’ toxicity in human 
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neuronal cells, and possibly the biochemical mechanisms underlying 
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1.1. Introduction 
Nanomaterials are appealing and valuable in various fields, 
as they are engineered to achieve particular physicochemical 
properties that are specific for their application. However, serious 
health considerations have been considered. The most prevalent 
toxicity mechanism for AgNPs is oxidative stress. Multiple studies have 
found that AgNPs preferentially disrupt mitochondrial function, since 
mitochondria are major ROS producers. AgNPs exposure led to 
damaged mitochondrial membrane, reduced mitochondrial membrane 
potential, opening of MPTP, disruption of ETC, reduced ATP 
production, and eventually cell death (AshaRani et al., 2009, Costa et 
al., 2010, Piao et al., 2011, Teodoro et al., 2011, Mukherjee et al., 
2012, Chairuangkitti et al., 2013, Stensberg et al., 2013). On the other 
hand, there are conflicting reports of AuNPs’ toxicity. Several studies 
have demonstrated that AuNPs do not show overt toxicity (Connor et 
al., 2005, Zhang et al., 2010, Asharani et al., 2011). However, Li et al. 
(2008) determined that AuNPs inhibited cell proliferation, and induced 
oxidative damage and cytotoxicity in human lung fibroblasts. It has 
been suggested that the cytotoxicity of AuNPs is largely dependent on 
its physical properties (Goodman et al., 2004, Pan et al., 2007). When 
compared to AgNPs, AuNPs are noticeably less toxic (Bar-Ilan et al., 
2009). 
DHA is the major fatty acid in brain, and is a structural 
component of neuronal (Horrocks and Farooqui, 2004) and 
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mitochondrial membranes (O'Shea et al., 2009, Khairallah et al., 2012). 
DHA is crucial in neuroprotection as it contains anti-oxidative stress, 
anti-inflammation, and anti-apoptotic properties (Eady et al., 2012, 
Tanaka et al., 2012). Fatty acids are transported into mitochondrial 
matrix for ATP production via the carnitine shuttle, involving LC (Walter 
and Schaffhauser, 2000, Hoppel, 2003). Essential for brain function, 
the lack of LC results in major detrimental consequences including the 
development of metabolic encephalopathy (Kimura and Amemiya, 
1990, Jones et al., 2010). LC effectively protects mitochondria and 
cells against oxidative stress, by inhibiting mitochondrial membrane 
depolarization and ROS formation, increasing mitochondrial functions, 
and preventing cell death in serum- or glucose-deprived medium 
(Virmani and Binienda, 2004, Hino et al., 2005, He et al., 2011, Geier 
and Geier, 2013). 
In this chapter, the relationship between AgNPs and 
mitochondria was examined. The possibility of DHA and/or LC 
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1.2. Materials and Methods 
1.2.1. Cell Culture 
SH-SY5Y cells (CRL-2266TM, ATCC®, Manassas, VA, USA) 
were cultured in Dulbecco’s Modified Eagle Medium containing 10 % 
heat-inactivated fetal bovine serum and 1 % penicillin-streptomycin 
(Gibco®, Life Technologies, Carlsbad, CA, USA). The combined 
medium is defined as complete growth medium in this thesis. SH-SY5Y 
cells were grown in 100 mm dishes, incubated under standard 
conditions of 37 °C and 5 % CO2, and regularly passaged with 0.25 % 
Trypsin-EDTA (Gibco®, Life Technologies, Carlsbad, CA, USA). 
 
1.2.2. Synthesis of AgNPs 
5 mL 2 mg/mL silver nitrate (AgNO3) solution (Merck 
Millipore, Billerica, MA, USA) was added to 75 mL reagent-grade water, 
and heated in a 65 °C silicone oil bath. The solution was stirred at 
1,000 rpm. A separate solution of 3.1 mL 1 mg/mL tannic acid solution 
(Sigma-Aldrich, St. Louis, MO, USA), 4 mL 10 mg/mL sodium citrate 
dihydrate solution (Sigma-Aldrich, St. Louis, MO, USA), and 12.9 mL 
reagent-grade water was warmed for 20 minutes in the oil bath, and 
subsequently combined with the AgNO3 solution. Temperature of oil 
bath was increased to 100 °C, and the solution was heated for an 
additional 20 minutes, during which solution color turned golden yellow 
(Fig. 3.1.1). Synthesized AgNPs were cooled to room temperature prior 
to storing at 4 °C in the dark. 
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Fig. 3.1.1 Schematic diagram of the set up used for NPs synthesis (not 
drawn to scale). Solutions were heated in a temperature controlled 
silicone oil bath. A condenser was fitted onto the set up to prevent loss 
of solution due to vapor formation during the heating process. 
 
1.2.3. Purification of AgNPs 
8 mL synthesized AgNPs suspension was centrifuged at 
5,000 g for 30 minutes at 4 °C. Supernatant (S1) was separated and 
centrifuged with identical parameters to retrieve remaining AgNPs. 
AgNPs pellet (P1) was resuspended with 8 mL reagent-grade water. 
After S1 centrifugation, supernatant (S2) was decanted and AgNPs 
pellet (P2) added to existing AgNPs suspension. The process was 
repeated, and final pellets (P3 and 4) were resuspended in 8 mL 
















 DHA and LC prevent acute silver nanotoxicity	   	  
42 
      
Fig. 3.1.2 Schematic diagram of AgNPs purification process. AgNPs 
suspension was purified twice to remove potential contaminants, using 
the following conditions: 5,000 g at for 30 minutes 4 °C. Adapted from 
Balasubramanian et al. (2010). 
 
8 mL synthesized 
AgNPs suspension!
Centrifuge at 5,000 g for 30 
minutes at 4 °C!
Supernatant (S1)! AgNPs pellet (P1)!




Centrifuge at 5,000 g for 30 
minutes at 4 °C!
Centrifuge at 5,000 g for 30 
minutes at 4 °C!
S3! P3!
Resuspend P3 in 8 mL 
complete growth medium!
S4!
Centrifuge at 5,000 g for 30 
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1.2.4. Synthesis of AuNPs 
AuNPs synthesis was conducted as previously described by 
Turkevich et al. (1951). 100 μL 10 % (w/v) gold chloride hydrate 
solution (Sigma-Aldrich, St. Louis, MO, USA) was added to 95 mL 
reagent-grade water, warmed in a 100 °C silicone oil bath, and stirred 
at 1,000 rpm. A separate solution of 5 mL 1 % sodium citrate dihydrate 
solution was heated for 20 minutes in the oil bath, and combined with 
the gold chloride hydrate solution. The solution was heated for an 
additional 20 minutes, during which solution color turned wine-red. 
Synthesized AuNPs were cooled to room temperature prior to storing at 
4 °C in the dark.  
 
1.2.5. Purification of AuNPs 
540 μL synthesized AuNPs suspension was centrifuged at 
7,000 g for 20 minutes at 4 °C. Supernatant (S1) was separated and 
centrifuged with identical parameters to retrieve remaining AuNPs. 
AuNPs pellet (P1) was resuspended in 540 μL reagent-grade water. 
After S1 centrifugation, supernatant (S2) was decanted and AuNPs 
pellet (P2) added to existing AuNPs suspension. The process was 
repeated, and final pellets (P3 and 4) were resuspended in 540 μL 
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1.2.6. Characterization of AgNPs and AuNPs 
Concentration, hydrodynamic size, and polydispersity of 
NPs were analyzed via dynamic light scattering measurements, using 
the Zetasizer Nano ZS (Malvern Instruments, Worcestershire, England, 
UK). General morphology, size, and possible aggregation of NPs were 
determined using Philips CM120 BioTwin transmission electron 
microscope (FEI Philips, Hillsboro, OR, USA). 
 
1.2.7. Trypan Blue Exclusion Cell Viability Assay 
SH-SY5Y cells were plated in a 6-well plate at 0.5 X 106 
cells/well, and allowed to attach overnight. Four groups of cells were 
treated with the following reagents: (1) vehicle, water, (2) 78.7 μg/mL 
AgNO3, (3) 50 μg/mL AgNPs, (4) 91.3 μg/mL AuNPs, and incubated for 
one hour. Phosphate buffered saline (PBS, pH 7.4) was used to wash 
the cells. SH-SY5Y cells were then exposed to 0.4 % trypan blue 
solution (Sigma-Aldrich, St. Louis, MO, USA) for five minutes, and 
viable cells percentage determined.  
 
1.2.8. Mitochondrial Membrane Potential Assay 
SH-SY5Y cells were plated in a 24-well plate at 1.0 X 105 
cells/well, and allowed to attach overnight. Three groups of cells were 
treated with the following reagents: (1) negative control: vehicle, water, 
(2) positive control: vehicle, water, (3) 50 μg/mL AgNPs, and incubated 
for one hour. PBS was used to wash the cells. SH-SY5Y cells were 
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then incubated with 0.5 μM 5,5’,6,6’-tetrachloro-1,1’,3,3’-
tetraethylbenzimidazolylcarbocyanine iodide (JC-1 dye) (Molecular 
Probes®, Life Technologies, Carlsbad, CA, USA) at 37 °C for 20 
minutes in Earl’s balanced salt solution (EBSS) (Sigma-Aldrich, St. 
Louis, MO, USA). PBS was used to wash the cells. EBSS with dimethyl 
sulfoxide (DMSO) (Sigma-Aldrich, St. Louis, MO, USA) was 
supplemented to negative control and AgNPs-treated cells, while 
positive control was given 5 μM carbonyl cyanide 3-
chlorophenylhydrazone (CCCP) (Santa Cruz Biotechnology, Dallas, 
TX, USA). Samples were read with the Tecan Infinite® 200 microplate 
reader (Männedorf, Switzerland) using excitation and emission 
wavelengths of 488 nm and 535 nm for green fluorescence and 590 
nm for red fluorescence. Cells were analyzed at two-minute intervals 
for 30 minutes. Red/green fluorescence (590/535) ratios were taken as 
an expression of mitochondrial membrane potential. 
 
1.2.9. ADP/ATP Ratio Assay 
1.2.9.1. Treatment with AgNPs, DHA and LC 
SH-SY5Y cells were plated in a 96-well plate at 1.0 X 104 
cells/well, and allowed to attach overnight. Five groups of cells were 
treated with the following reagents: (1) vehicle, ethanol and water, (2) 
50 μg/mL AgNPs, (3) 50 μg/mL AgNPs and 10 μM DHA (Cayman 
Chemical, Ann Arbor, MI, USA), (4) 50 μg/mL AgNPs and 100 μM LC 
(Sigma-Aldrich, St. Louis, MO, USA), (5) 50 μg/mL AgNPs, 10 μM 
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DHA, and 100 μM LC, and incubated for one hour. PBS was used to 
wash the cells. The assay was then carried out according to the 
manufacturer’s instructions (Abcam, Cambridge, UK). Briefly, SH-SY5Y 
cells were exposed to nucleotide releasing buffer (NRB) for 10 minutes 
with gentle agitation. Concurrently, a reaction mix containing NRB and 
ATP monitoring enzyme was added into each well of a 96-well white-
walled luminometer plate. After 10 minutes, the lysed cells were 
transferred into the white-walled luminometer plate, and allowed to sit 
for an additional 10 minutes. Samples were then read using the Tecan 
Infinite® 200 microplate reader (Data A). Samples were analyzed again 
after 10 minutes (Data B). ADP converting enzyme was added to the 
samples, and samples were analyzed after another 10 minutes (Data 
C). Intracellular ADP/ATP ratios were determined using the following 
equation: 
Data C  -  Data B
Data A  
 
1.2.9.2. Treatment with AgNPs and AuNPs 
SH-SY5Y cells were plated in a 96-well plate at 1.0 X 104 
cells/well, and allowed to attach overnight. Three groups of cells were 
treated with the following reagents: (1) vehicle, water, (2) 50 μg/mL 
AgNPs, (3) 91.3 μg/mL AuNPs, and incubated for one hour. PBS was 
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1.2.10. Statistical Analyses 
Mean and standard error of values were determined for 
each experimental group, and possible significant differences among 
various groups were analyzed using one-way ANOVA with Bonferroni’s 
multiple comparison post-hoc test. p < 0.05 was deemed significant. 
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1.3. Results 
1.3.1. Characterization of AgNPs and AuNPs 
AgNPs and AuNPs were roughly spherical, with an 
approximate diameter of 26 nm for AgNPs (Fig. 3.1.3) and 20 nm for 
AuNPs (Fig. 3.1.4). AgNPs and AuNPs suspension concentrations 
were determined to be 50 μg/mL and 91.3 μg/mL respectively. Number 
of particles was equivalent in both suspensions, at 2.79 X 1017 
particles/mL, signifying that subsequent experiments were centered on 
number of particles, which is a better design.  
 
 
Fig. 3.1.3 TEM micrograph of AgNPs used in the present study. AgNPs 
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Fig. 3.1.4 TEM micrograph of AuNPs used in the present study. AuNPs 
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1.3.2. Trypan Blue Exclusion Cell Viability Assay Analysis 
One hour incubation of SH-SY5Y cells with 78.7 μg/mL 
AgNO3 resulted in rapid cell death, with an observed cell viability of 
0.99 % (Fig. 3.1.5). Cell viabilities of vehicle control, 50 μg/mL AgNPs-, 
and 91.3 μg/mL AuNPs-treated SH-SY5Y cells after one hour 
incubation were 92.98 %, 94.52 %, and 92.77 % respectively. 
Significant differences were observed between 78.7 μg/mL AgNO3-
treated cells and vehicle control, 50 μg/mL AgNPs-, and 91.3 μg/mL 
AuNPs-treated cells (p < 0.001). 
 
 
Fig. 3.1.5 Cell viability of SH-SY5Y cells following one hour incubation 
with various treatment groups – vehicle control; 78.7 μg/mL AgNO3; 50 
μg/mL AgNPs; 91.3 μg/mL AuNPs (n = 4 in each group). Each bar in 
the figure denotes mean + SEM. Asterisks (*) indicate significant 
differences in cell viability by one-way ANOVA with Bonferroni’s 
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1.3.3. Mitochondrial Membrane Potential Assay Analysis 
One hour incubation of SH-SY5Y cells with 50 μg/mL AgNPs 
resulted in a significant reduction in 590/535 ratio compared to 
negative control over time (p < 0.001) (Fig. 3.1.6). Similarly, positive 
control showed a significant decrease in 590/535 ratio compared to 
negative control over time (p < 0.001). 
 
 
Fig. 3.1.6 Mitochondrial membrane potential of SH-SY5Y cells 
following one hour incubation with various treatment groups – negative 
control; 50 µg/mL AgNPs; 5 µM CCCP (positive control) (n = 4 in each 
group). Each time point represents a two-minutes interval. Asterisks (*) 
indicate significant differences in 590/535 ratio compared to negative 
control by one-way ANOVA with Bonferroni’s multiple comparison post-
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1.3.4. ADP/ATP Ratio Assay Analyses 
1.3.4.1. Treatment with AgNPs, DHA, and LC 
1.3.4.1.1. ATP Levels 
One hour incubation of SH-SY5Y cells with 50 μg/mL AgNPs 
resulted in a 0.63-fold (p < 0.001) statistically significant change in ATP 
levels compared to vehicle control (Fig. 3.1.7). There was a 0.71-fold (p 
< 0.001), 0.79-fold (p < 0.001), and 1.05-fold (p = 1.00) change in ATP 
levels in cells treated with the various rescue efforts – 50 μg/mL AgNPs 
+ 10 μM DHA, 50 μg/mL AgNPs + 100 μM LC, and 50 μg/mL AgNPs + 
10 μM DHA + 100 μM LC – compared to vehicle control. Compared to 
50 μg/mL AgNPs-treated SH-SY5Y cells, significant increases in ATP 
levels were observed in cells treated with 50 μg/mL AgNPs + 10 μM 
DHA (p = 0.033), 50 μg/mL AgNPs + 100 μM LC (p < 0.001), and 50 
μg/mL AgNPs + 10 μM DHA + 100 μM LC (p < 0.001). Statistically 
significant increases in ATP levels were also observed in cells treated 
with 50 μg/mL AgNPs + 10 μM DHA + 100 μM LC compared to 50 
μg/mL AgNPs + 10 μM DHA (p < 0.001) and 50 μg/mL AgNPs + 100 
μM LC (p < 0.001). 
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Fig. 3.1.7 Fold change in ATP levels of SH-SY5Y cells following one 
hour incubation with various treatment groups – vehicle control; 50 
μg/mL AgNPs; 50 μg/mL AgNPs + 10 μM DHA; 50 μg/mL AgNPs + 
100 μM LC; 50 μg/mL AgNPs + 10 μM DHA + 100 μM LC (n = 6 in 
each group). Each bar in the figure denotes mean + SEM. Asterisks (*) 
indicate significant differences in fold change by one-way ANOVA with 
Bonferroni’s multiple comparison post-hoc test. * p < 0.05, p < 0.01,  
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1.3.4.1.2. ADP Levels 
One hour incubation of SH-SY5Y cells with 50 μg/mL AgNPs 
resulted in a 0.79-fold (p < 0.001) statistically significant change in ADP 
levels compared to vehicle control (Fig. 3.1.8). There was a 0.80-fold (p 
< 0.001), 0.78-fold (p < 0.001), and 0.88-fold (p = 0.003) change in 
ADP levels in cells treated with the various rescue efforts – 50 μg/mL 
AgNPs + 10 μM DHA, 50 μg/mL AgNPs + 100 μM LC, and 50 μg/mL 
AgNPs + 10 μM DHA + 100 μM LC – compared to vehicle control. 
Statistically significant increases in ADP levels were also observed in 
cells treated with 50 μg/mL AgNPs + 10 μM DHA + 100 μM LC 
compared to 50 μg/mL AgNPs (p = 0.021) and 50 μg/mL AgNPs + 100 
μM LC (p = 0.011). 
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Fig. 3.1.8 Fold change in ADP levels of SH-SY5Y cells following one 
hour incubation with various treatment groups – vehicle control; 50 
μg/mL AgNPs; 50 μg/mL AgNPs + 10 μM DHA; 50 μg/mL AgNPs + 
100 μM LC; 50 μg/mL AgNPs + 10 μM DHA + 100 μM LC (n = 6 in 
each group). Each bar in the figure denotes mean + SEM. Asterisks (*) 
indicate statistically significant differences in fold change by one-way 
ANOVA with Bonferroni’s multiple comparison post-hoc test. * p < 0.05, 
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1.3.4.1.3. ADP/ATP Ratio 
One hour incubation of SH-SY5Y cells with 50 μg/mL AgNPs 
resulted in a 1.25-fold (p < 0.001) statistically significant increase in 
ADP/ATP ratio compared to vehicle control (Fig. 3.1.9). There was a 
1.13-fold (p < 0.001), 0.98-fold (p = 1.00), and 0.84-fold (p < 0.001) 
change in ADP/ATP ratio in cells treated with the various rescue efforts 
– 50 μg/mL AgNPs + 10 μM DHA, 50 μg/mL AgNPs + 100 μM LC, and 
50 μg/mL AgNPs + 10 μM DHA + 100 μM LC – compared to vehicle 
control. Compared to 50 μg/mL AgNPs-treated SH-SY5Y cells, 
significant decreases in ADP/ATP ratio were observed in cells treated 
with 50 μg/mL AgNPs + 10 μM DHA (p = 0.002), 50 μg/mL AgNPs + 
100 μM LC (p < 0.001), and 50 μg/mL AgNPs + 10 μM DHA + 100 μM 
LC (p < 0.001). Statistically significant decreases in ADP/ATP ratio 
were also observed in cells treated with 50 μg/mL AgNPs + 10 μM 
DHA + 100 μM LC compared to 50 μg/mL AgNPs + 10 μM DHA (p < 
0.001) and 50 μg/mL AgNPs + 100 μM LC (p < 0.001). 
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Fig. 3.1.9 Fold change in ADP/ATP ratio of SH-SY5Y cells following 
one hour incubation with various treatment groups – vehicle control; 50 
μg/mL AgNPs; 50 μg/mL AgNPs + 10 μM DHA; 50 μg/mL AgNPs + 
100 μM LC; 50 μg/mL AgNPs + 10 μM DHA + 100 μM LC (n = 6 in 
each group). Each bar in the figure denotes mean + SEM. Asterisks (*) 
indicate statistically significant differences in fold change by one-way 
ANOVA with Bonferroni’s multiple comparison post-hoc test.  
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1.3.4.2. Treatment with AgNPs and AuNPs 
1.3.4.2.1. ATP Levels 
One hour incubation of SH-SY5Y cells with 91.3 μg/mL 
AuNPs resulted in a 1.36-fold (p < 0.001) statistically significant 
increase in ATP levels compared to vehicle control (Fig. 3.1.10). 
Similar to previous findings, 50 μg/mL AgNPs-treated SH-SY5Y cells 
led to a 0.47-fold (p < 0.001) statistically significant change in ATP 
levels compared to vehicle control. 
 
 
Fig. 3.1.10 Fold change in ATP levels of SH-SY5Y cells following one 
hour incubation with various treatment groups – vehicle control; 50 
μg/mL AgNPs; 91.3 μg/mL AuNPs (n = 6 in each group). Each bar in 
the figure denotes mean + SEM. Asterisks (*) indicate statistically 
significant differences in fold change by one-way ANOVA with 
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1.3.4.2.2. ADP Levels 
One hour incubation of SH-SY5Y cells with 91.3 μg/mL 
AuNPs resulted in a 0.96-fold (p = 1.00) change in ADP levels 
compared to vehicle control (Fig. 3.1.11). Similar to previous findings, 
50 μg/mL AgNPs-treated SH-SY5Y cells led to a 0.70-fold (p < 0.001) 




Fig. 3.1.11 Fold change in ADP levels of SH-SY5Y cells following one 
hour incubation with various treatment groups – vehicle control; 50 
μg/mL AgNPs; 91.3 μg/mL AuNPs (n = 6 in each group). Each bar in 
the figure denotes mean + SEM. Asterisks (*) indicate statistically 
significant differences in fold change by one-way ANOVA with 
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1.3.4.2.3. ADP/ATP Ratio 
One hour incubation of SH-SY5Y cells with 91.3 μg/mL 
AuNPs resulted in a 0.70-fold (p = 0.004) statistically significant change 
in ADP/ATP ratio compared to vehicle control (Fig. 3.1.12). Similar to 
previous findings, 50 μg/mL AgNPs-treated SH-SY5Y cells led to a 
1.46-fold (p < 0.001) statistically significant increase in ADP/ATP ratio 
compared to vehicle control. 
 
 
Fig. 3.1.12 Fold change in ADP/ATP ratio of SH-SY5Y cells following 
one hour incubation with various treatment groups – vehicle control; 50 
μg/mL AgNPs; 91.3 μg/mL AuNPs (n = 6 in each group). Each bar in 
the figure denotes mean + SEM. Asterisks (*) indicate statistically 
significant differences in fold change by one-way ANOVA with 
Bonferroni’s multiple comparison post-hoc test. ** p < 0.01,  
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1.4. Discussion 
This chapter was conducted to investigate the acute effects 
of AgNPs in SH-SY5Y human neuroblastoma mitochondria, and 
possibly rescue the AgNPs-induced mitochondrial dysfunction through 
the use of DHA and LC. SH-SY5Y is a subclone from SK-N-SH, an 
uncloned neuroblastoma line (Biedler et al., 1978, Lopes et al., 2010, 
Yusuf et al., 2013). Due to its capacity to acquire neuron-like 
phenotypes, SH-SY5Y is frequently used as a neuronal model (Lopes 
et al., 2010, Yusuf et al., 2013). Additionally, cell lines are easy to 
manipulate, with infinite lifespans when handled appropriately (ATCC, 
2012). Therefore, SH-SY5Y human neuroblastoma cells were selected 
to investigate the effects of AgNPs. 
The selected AgNPs concentration, 50 μg/mL, is based on 
previous cell culture studies that utilized AgNPs, where changes in 
mitochondrial function and cell morphology were detected (Hussain et 
al., 2005, Arora et al., 2008, Hsin et al., 2008). AgNO3 and AuNPs 
concentrations were chosen to match the number of Ag and Au 
particles in the respective solutions to Ag particles in 50 μg/mL AgNPs 
suspension, at approximately 2.79 X 1017 particles/mL. AgNPs have 
been reported to release Ag ions over time (AshaRani et al., 2009, 
Kittler et al., 2010, Liu and Hurt, 2010, Yu et al., 2013). Hence, AgNO3 
solution was used as a control, to distinguish between effects of Ag 
nanoparticulates and Ag ions in solution. By determining number of 
AgNPs in suspension, total amount of Ag atoms was calculated and 
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converted to the concentration of AgNO3 solution required, in the event 
that all atoms went into solution as Ag ions. After one hour incubation, 
AgNO3-treated cells exhibited 0.99 % cell viability, while 94 % of 
AgNPs-treated cells survived. This reveals that AgNPs are much less 
hazardous as compared to Ag ions in solution, and indicates that 
results obtained from AgNPs-treated SH-SY5Y cells in subsequent 
assays are mainly due to the actions of AgNPs. Since incubation with 
AgNO3 led to death of almost all SH-SY5Y cells, it was not used in 
other experiments. 
 Mitochondrial membrane potential is generated from the 
presence of an electrochemical gradient across the inner mitochondrial 
membrane (Alberts et al., 2008, Voet et al., 2013). JC-1 dye is used to 
indicate status of mitochondria as it accumulates as red fluorescence 
aggregates in healthy cell mitochondria but stays in its cytoplasmic 
green monomeric form when mitochondrial membrane depolarizes (Ma 
et al., 2011, Guo et al., 2013). Acute exposure of AgNPs to SH-SY5Y 
cells led to a drop in 590/535 ratio, similar to CCCP, the positive 
control, suggesting mitochondrial membrane damage. CCCP is a well-
characterized protonophore. Exposure of CCCP to cells causes rapid 
loss of mitochondrial membrane potential and mitochondrial 
morphological swelling (Minamikawa et al., 1999, Lim et al., 2001, 
Perry et al., 2011). This corroborates with results from previous studies 
where AgNPs affected mitochondria of non-neuronal cells, determined 
by TPP+ – selective electrode (Teodoro et al., 2011) and rhodamine 
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123 uptake (Hussain et al., 2005). Mitochondrial membrane 
depolarization and oxidative stress are important cellular occurrences 
that often precede the induction of apoptosis (Taggart et al., 2014). 
However, the incubation period of one hour in the current study was 
probably too short for apoptosis to occur, as demonstrated by the lack 
of significant cell death in the trypan blue exclusion cell viability assay.  
ATP levels decreased in AgNPs-treated cells indicating 
possible damage to mitochondrial respiratory chain (AshaRani et al., 
2009, Costa et al., 2010). AgNPs have been reported to cause 
oxidative stress and calcium dysregulation in cells (Haase et al., 2012). 
In order to restore intracellular calcium levels, the Ca2+ ATPase pump 
or Na+/Ca2+ exchanger could be activated, leading to increased 
intracellular sodium and Na+/K+ ATPase pump activity to maintain 
resting potential (Wang et al., 2003, Alberts et al., 2008). Therefore, 
usage of these pumps could in turn result in lowered ATP levels in 
cells. Another reason for the observed reduction in ATP levels could be 
due to cell lysis and release of intracellular ATP (Suszynski et al., 
2008). Nevertheless, this is unlikely as negligible cell death was 
observed for AgNPs-treated cells as compared to vehicle control in the 
current study. As ATP levels decline, a corresponding rise in ADP 
levels is expected since ATP hydrolyzes to form ADP (Alberts et al., 
2008, Myhill et al., 2009, Voet et al., 2013). Conversely, a decrease in 
ADP levels was detected. This could possibly be due to the action of 
adenylate kinase (AK), a phosphotransferase that catalyzes the 
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conversion of ADP to ATP and adenosine monophosphate (AMP) 
(Alberts et al., 2008, Voet et al., 2013). Under conditions of low ATP 
levels, AK compensates by using two ADP molecules to generate more 
ATP and in the process produce AMP, which can be degraded by AMP 
deaminase to give rise to inosine monophosphate (IMP), preventing 
the recycling of AMP to ADP and ATP (Myhill et al., 2009). This 
decreases the adenine nucleotide source and diminishes ADP and 
ATP stores. 
 Studies have demonstrated protective properties of DHA 
and LC against mitochondrial dysfunction and neuronal injury 
(Horrocks and Farooqui, 2004, Virmani and Binienda, 2004, Alves et 
al., 2009, He et al., 2011). Co-incubation of SH-SY5Y cells with AgNPs 
and DHA led to greater ATP and ADP levels compared to AgNPs-
treated cells only, suggesting that DHA was capable of partially 
reversing damage caused by acute AgNPs exposure. DHA is 
incorporated in both cell (Horrocks and Farooqui, 2004) and 
mitochondrial membrane phospholipids (O'Shea et al., 2009, Khairallah 
et al., 2012), and could repair AgNPs-induced damage to these 
membranes. Moreover, co-supplementation of DHA and LC was even 
more effective at preventing AgNPs-induced drop in ATP levels. 
Statistically significant differences were also detected between cells 
treated with AgNPs + DHA and AgNPs + DHA + LC, and cells treated 
with AgNPs + LC and AgNPs + DHA + LC, possibly indicating a 
synergistic association between DHA and LC. The main function of LC 
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is to facilitate fatty acid transport, such as DHA, into mitochondrial 
matrix for the production of ATP via β-oxidation (Kerner and Hoppel, 
2000, Walter and Schaffhauser, 2000, Hoppel, 2003). LC is also crucial 
for protection against mitochondrial dysfunction (Ishii et al., 2000, 
Virmani and Binienda, 2004, Hino et al., 2005, He et al., 2011, Geier 
and Geier, 2013). It is hypothesized that the effectiveness of co-
supplementation of DHA and LC in diminishing AgNPs’ harmful effects 
could be because LC aids in the transport of DHA into mitochondria for 
the incorporation of DHA into mitochondrial phospholipids to repair 
damaged phospholipids affected by AgNPs’ attack. 
As AuNPs are usually associated with low or no cytotoxicity 
(Connor et al., 2005, Bar-Ilan et al., 2009, Asharani et al., 2011), 
AuNPs were used as a positive control in the study. As expected, one 
hour incubation with AuNPs did not lead to significant cell death, 
indicating its relative non-toxicity. However, AuNPs may demonstrate 
other cellular damage. Incubation of SH-SY5Y cells with AuNPs for one 
hour led to increased ATP levels, no changes in ADP levels, and 
decreased ADP/ATP ratio as compared to vehicle control. This could 
possibly be due to depressed cellular processes following the one hour 
incubation with AuNPs, resulting in decreased consumption of ATP, 
and consequently, an accumulation of ATP. Lack of significant 
alterations in ADP levels following AuNPs exposure suggests that ATP 
is unlikely to be synthesized. Several studies have shown that 
exposure to AuNPs led to a depression of ATP-dependent cellular 
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processes such as cell proliferation, cell cycle progression, and motility 
(Pernodet et al., 2006, Balasubramanian et al., 2010, Liu et al., 2014). 
The reduction in ATP expenditure could contribute to the observed 
accumulation of ATP following one hour incubation with AuNPs. 
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2.1.       Introduction 
In the previous chapter, it was established that acute 
exposure of AgNPs to SH-SY5Y cells resulted in mitochondrial 
dysfunction and subsequently decreased ATP production, without 
leading to cell death. The harmful effects exerted by AgNPs were 
rescued through the co-supplementation of DHA and LC. Apart from 
disrupting mitochondrial function, nanotoxicity is often associated with 
the triggering of inflammatory responses (Park and Park, 2009, Xue et 
al., 2012, Panas et al., 2013). AgNPs exposure in various cell lines led 
to the induction of inflammation (Romoser et al., 2012, Prasad et al., 
2013). Additionally, mice (Cha et al., 2008) and rats (Kim et al., 2010) 
exposed to AgNPs showed changes in expression of genes and 
proteins that moderate ROS formation, inflammation, and apoptosis. 
On the contrary, AuNPs do not show overt toxicity, although it could be 
identified as foreign materials by immune cells, leading to acute 
inflammation and apoptosis (Cho et al., 2009). 
PLA2 enzymes play integral roles in brain and are crucial for 
signal transduction, production of eicosanoids and lipid mediators, 
inflammation, membrane remodeling, and lipid metabolism (Dennis, 
1997, Farooqui et al., 2000, Ong et al., 2010, Sun et al., 2014). Under 
normal conditions, PLA2 enzymes prevent membrane lipid peroxidation 
through the removal of oxidized fatty acids from phospholipids (Tan et 
al., 1984, Sevanian and Kim, 1985, McLean et al., 1993, Ong et al., 
2015). In pathological conditions however, elevated activation of PLA2 
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enzymes result in increased production of fatty acids and 
lysophospholipids that will be metabolized to form second messengers 
and metabolites that could lead to inflammation (Sun et al., 2014, Ong 
et al., 2015). cPLA2 preferentially releases AA from 
glycerophospholipids (Murakami and Kudo, 2002, Sun et al., 2004, 
Ong et al., 2015), where AA becomes precursors for eicosanoids and 
prostanoids, which lead to inflammatory responses in cells (Calder, 
2008, Sun et al., 2014). Elevated cPLA2 activity is often associated with 
oxidative stress and neuroinflammation (Ong et al., 2003, Farooqui and 
Horrocks, 2006, Tanaka et al., 2012). On the other hand, iPLA2 
mediates release of DHA, which is further metabolized to docosanoids 
that antagonize effects of AA-derived pro-inflammatory eicosanoids 
thus exhibiting anti-inflammatory and anti-apoptotic characteristics 
(Mukherjee et al., 2004, Bazan, 2009, Ong et al., 2015). 
In this chapter, the relationship between AgNPs and PLA2 
enzymes, in particular cPLA2 and iPLA2, was examined. The 
mechanism underlying AgNPs-induced inflammatory responses in SH-
SY5Y cells – induction of cPLA2, depression of iPLA2 expression and 
function, or both – was also determined.  
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2.2.       Materials and Methods 
2.2.1.      Cell Culture 
SH-SY5Y cells were cultured in complete growth medium, 
and grown in 100 mm dishes. SH-SY5Y cells were incubated under 
standard conditions of 37 °C and 5 % CO2, and regularly passaged 
with 0.25 % Trypsin-EDTA. At 70 % confluence, cells were used for 
treatments. 
 
2.2.2. Synthesis, Purification, and Characterization of AgNPs 
and AuNPs 
26 nm AgNPs and 20 nm AuNPs were synthesized, purified, 
and characterized as described in chapter 1 (pages 40 – 43). 
 
2.2.3. Trypan Blue Exclusion Cell Viability Assay 
SH-SY5Y cells were plated in a 6-well plate at 0.5 X 106 
cells/well, and allowed to attach overnight. Three groups of cells were 
treated with the following reagents: (1) vehicle, water, (2) 50 μg/mL 
AgNPs, (3) 91.3 μg/mL AuNPs, and incubated for six hours. PBS was 
used to wash the cells. The assay was then carried out as described in 
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2.2.4. Cell Treatment 
2.2.4.1. Treatment with AgNPs 
Two groups of SH-SY5Y cells were treated with the following 
reagents: (1) vehicle, water, (2) 50 μg/mL AgNPs, and were incubated 
for one and six hours. PBS was used to wash the cells. SH-SY5Y cells 
were then harvested for further real-time RT-PCR, 
immunocytochemistry, and lipidomic profiling analyses. 
 
2.2.4.2. Treatment with AgNPs and AuNPs 
Three groups of SH-SY5Y cells were treated with the 
following reagents: (1) vehicle, water, (2) 50 μg/mL AgNPs, (3) 91.3 
μg/mL AuNPs, and incubated for one and six hours. PBS was used to 
wash the cells. SH-SY5Y cells were then harvested for further real-time 
RT-PCR analyses. 
 
2.2.4.3. Treatment with AgNPs, DHA, and LC 
Eight groups of SH-SY5Y cells were treated with the 
following reagents: (1) vehicle, ethanol and water, (2) 10 μM DHA, (3) 
100 μM LC, (4) 10 μM DHA and 100 μM LC, (5) 50 μg/mL AgNPs, (6) 
50 μg/mL AgNPs + 10 μM DHA, (7) 50 μg/mL AgNPs + 100 μM LC, (8) 
50 μg/mL AgNPs + 10 μM DHA + 100 μM LC, and incubated for six 
hours. PBS was used to wash the cells. SH-SY5Y cells were then 
harvested for further real-time RT-PCR analysis.  
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2.2.5. Real-time RT-PCR 
RNeasy Mini Kit (Qiagen, Venlo, Limburg, Netherlands) was 
used to extract and purify RNA of treated cells, which was then reverse 
transcribed using High-Capacity cDNA Reverse Transcription Kits 
(Applied Biosystems®, Life Technologies, Carlsbad, CA, USA) with the 
stated reaction parameters: 10 minutes at 25 °C, 120 minutes at 37 °C, 
and 5 minutes at 85 °C. Using a 7,500 Real-time PCR system, real-
time PCR amplification was carried out with the following reagents: 
TaqMan® Universal PCR Master Mix (#4304437) and probes for 
human cPLA2 (Hs00233352_m1), iPLA2 (Hs00185926_m1), and ACTB 
(beta actin) (#4326315E) (Applied Biosystems®, Life Technologies, 
Carlsbad, CA, USA), and with the stated parameters: 2 minutes at 50 
°C, 10 minutes at 95 °C, 40 15 seconds cycles at 95 °C, and 1 minute 
at 60 °C. Amplified transcripts were quantified using the comparative 
threshold cycle (CT) method (Livak and Schmittgen, 2001), where 
relative fold change is calculated with the following equation: 
2-ΔΔCT 
CT is the number of cycles where reporter fluorescence 
emission surpasses preset threshold level. CT value inversely 
correlates with target mRNA levels. 
 
2.2.6. Immunocytochemistry 
SH-SY5Y cells were plated on poly-L-lysine (Sigma-Aldrich, 
St. Louis, MO, USA) coated coverslips in a 24-well plate at 2.0 X 105 
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cells/well, and allowed to attach overnight. Two groups of cells were 
treated with the following reagents: (1) vehicle, water, (2) 50 μg/mL 
AgNPs, and incubated for six hours. PBS was used to wash the cells. 
SH-SY5Y cells were then fixed with 2 % paraformaldehyde (PanReac 
AppliChem, Barcelona, Spain), washed with PBS, and reacted with 70 
% formic acid (Sigma-Aldrich, St. Louis, MO, USA) for 20 minutes and 
0.1 % PBS-Triton® X-100 (USB Corporation, Cleveland, OH, USA) for 
15 minutes. Cells were incubated with 1 % bovine serum albumin 
(BSA) (Calbiochem®, Merck Millipore, Billerica, MA, USA) in PBS for 
one hour, and anti-iPLA2 antibody (#160507, Cayman Chemical, Ann 
Arbor, MI, USA; diluted 1:50) in 1 % BSA overnight at 4 °C. PBS was 
used to wash the cells. SH-SY5Y cells were incubated with Alexa 
Fluor® 488 Donkey Anti-Rabbit lgG (H+L) Antibody (Applied 
Biosystems®, Life Technologies, Carlsbad, CA, USA; diluted 1:200) for 
one hour at room temperature, and subsequently mounted onto 
microscope slides using ProLong Gold anti-fade reagent with DAPI 
(InvitrogenTM, Life Technologies, Carlsbad, CA, USA), which is also 
used for nuclear counterstaining. Cells were viewed using the Olympus 
FluoView FV1000 confocal microscope at 40 X magnification. Total cell 
fluorescence corrected for background was determined with ImageJ 
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2.2.7. Lipidomic Profiling 
2.2.7.1. Lipid Extraction 
Lipid extraction was conducted using a modified protocol 
from Bligh and Dyer (1959). SH-SY5Y cells were passed through 27 G 
needles and sonicated in 750 μL chloroform/methanol, 1:2 (v/v) and 5 
μL of internal standards solution containing PC 14:0 14:0, LysoPC 
20:0, PE 14:0 14:0, PS 14:0 14:0, SM 30:1, and Cer 17:0 (Avanti Polar 
Lipids, Alabaster, AL, USA) for 30 minutes at 4 °C. Samples were 
supplemented with 250 μL chloroform and 450 μL 0.88 % potassium 
chloride solution, and centrifuged for two minutes at 9,000 g at 4 °C. 
250 μL chloroform was used to re-extract the aqueous phase and the 
organic fractions were combined, where the lipids were then isolated 
and vacuum-dried (Thermo ScientificTM SavantTM SpeedVacTM, Life 
Technologies, Carlsbad, CA, USA). 
 
2.2.7.2. Lipid Analysis 
Quantification of individual polar lipids was conducted using 
an Agilent HPLC-Chip system connected with an Agilent Technologies 
6460 Triple Quad LC/MS (Santa Clara, CA, USA), where the column 
used was Kinetex 2.6 μM HILIC 100 Å chip with a LC column of 150 X 
2.10 mm size. Solvents used were 50 % acetonitrile + 50 % 25 μM 
ammonium formate buffer pH 4.6 (solvent A) and 95 % acetonitrile + 5 
% 25 μM ammonium formate buffer pH 4.6 (solvent B). Analytes were 
eluted under the stated parameters: 0.1 % solvent A and 99.9 % 
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solvent B (0 to 6 minutes), 75 % solvent A and 25 % solvent B (6 to 7 
minutes), 90 % solvent A and 10 % solvent B (7 to 7.1 minutes), and 
0.1% solvent A and 99.9% solvent B (7.1 to 10.1 minutes) using a 
constant 0.5 mL/min flow rate. For the MS source parameters, gas 
temperature was set at 300 °C with a 5 L/min flow rate and nebulizer at 
45 psi. Sheath gas temperature was 250 °C with a 11 L/min gas flow 
rate. Data was then extracted and analyzed using the Agilent 
MassHunter acquisition, Agilent MassHunter Qualitative and Agilent 
MassHunter Quantitative software (Santa Clara, CA, USA). 
 
2.2.8. Statistical Analyses 
Mean and standard error of values were determined for 
each experimental group, and possible significant differences among 
various groups were analyzed using two-tailed unpaired Student’s t-test 
or one-way ANOVA with Bonferroni’s multiple comparison post-hoc 
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2.3. Results 
2.3.1. Real-time RT-PCR Analyses 
2.3.1.1. Effect of AgNPs Treatment on cPLA2 and iPLA2 mRNA 
Expression 
2.3.1.1.1. 1 Hour 
One hour incubation of SH-SY5Y cells with 50 μg/mL AgNPs 
resulted in a 1.26-fold (p = 0.44) change in cPLA2 mRNA expression 
compared to vehicle control (Fig. 3.2.1). 50 μg/mL AgNPs-treated SH-
SY5Y cells exhibited a 0.74 fold (p = 0.004) statistically significant 
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Fig. 3.2.1 Fold change in cPLA2 and iPLA2 mRNA expression in SH-
SY5Y cells following one hour incubation with vehicle control and 50 
μg/mL AgNPs (n = 4 in each group). Each bar in the figure denotes 
mean + SEM. Asterisks (*) indicate statistically significant differences in 
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2.3.1.1.2. 6 Hours 
Six hours incubation of SH-SY5Y cells with 50 μg/mL AgNPs 
resulted in a 1.12-fold (p = 0.69) change in cPLA2 mRNA expression 
compared to vehicle control (Fig. 3.2.2). 50 μg/mL AgNPs-treated SH-
SY5Y cells exhibited a 0.48 fold (p < 0.001) statistically significant 
change in iPLA2 mRNA expression compared to vehicle control. 
 
 
Fig. 3.2.2 Fold change in cPLA2 and iPLA2 mRNA expression in SH-
SY5Y cells following six hours incubation with vehicle control and 50 
μg/mL AgNPs (n = 4 in each group). Each bar in the figure denotes 
mean + SEM. Asterisks (*) indicate statistically significant differences in 
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2.3.1.2. Effect of AgNPs and AuNPs Treatment on iPLA2 mRNA 
Expression 
2.3.1.2.1. 1 Hour 
One hour incubation of SH-SY5Y cells with 91.3 μg/mL 
AuNPs resulted in a 0.48-fold (p < 0.001) statistically significant change 
in iPLA2 mRNA expression compared to vehicle control (Fig. 3.2.3). 
Similar to previous findings, 50 μg/mL AgNPs-treated SH-SY5Y cells 
led to a 0.74-fold (p = 0.006) statistically significant change in iPLA2 
mRNA expression compared to vehicle control. 
 
 
Fig. 3.2.3 Fold change in iPLA2 mRNA expression in SH-SY5Y cells 
following one hour incubation with various treatment groups – vehicle 
control; 50 μg/mL AgNPs; 91.3 μg/mL AuNPs (n = 4 in each group). 
Each bar in the figure denotes mean + SEM. Asterisks (*) indicate 
statistically significant differences in fold change by one-way ANOVA 
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2.3.1.2.2. 6 Hours 
Six hours incubation of SH-SY5Y cells with 91.3 μg/mL 
AuNPs resulted in a 0.97-fold (p = 1.000) change in iPLA2 mRNA 
expression compared to vehicle control (Fig. 3.2.4). Similar to previous 
findings, 50 μg/mL AgNPs-treated SH-SY5Y cells led to a 0.48-fold (p 
= 0.009) statistically significant change in iPLA2 mRNA expression 
compared to vehicle control. 
 
 
Fig. 3.2.4 Fold change in iPLA2 mRNA expression in SH-SY5Y cells 
following six hours incubation with various treatment groups – vehicle 
control; 50 μg/mL AgNPs; 91.3 μg/mL AuNPs (n = 4 in each group). 
Each bar in the figure denotes mean + SEM. Asterisks (*) indicate 
statistically significant differences in fold change by one-way ANOVA 
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2.3.1.3. Effect of AgNPs, DHA, and LC Treatment on iPLA2 mRNA 
Expression 
Six hours incubation of SH-SY5Y cells with 50 μg/mL AgNPs 
resulted in a 0.29-fold (p < 0.001) statistically significant change in 
iPLA2 mRNA expression compared to vehicle control (Fig. 3.2.5). 10 
μM DHA + 100 μM LC-treated cells exhibited a 0.51-fold (p = 0.016) 
significant change in iPLA2 mRNA expression compared to vehicle 
control. There was a 0.30-fold (p < 0.001), 0.34-fold (p < 0.001), and 
0.28-fold (p < 0.001) change in iPLA2 mRNA expression in cells treated 
with the various rescue efforts – 50 μg/mL AgNPs + 10 μM DHA, 50 
μg/mL AgNPs + 100 μM LC, and 50 μg/mL AgNPs + 10 μM DHA + 100 
μM LC – compared to vehicle control. Compared to 50 μg/mL AgNPs-
treated SH-SY5Y cells, no significant changes in iPLA2 mRNA 
expression were observed. Statistically significant reductions in iPLA2 
mRNA expression were also observed in cells treated with 10 μM DHA 
compared to 50 μg/mL AgNPs + 10 μM DHA (p < 0.001), and 100 μM 
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Fig. 3.2.5 Fold change in iPLA2 mRNA expression in SH-SY5Y cells 
following six hours incubation with various treatment groups – vehicle 
control; 10 μM DHA; 100 μM LC; 10 μM DHA + 100 μM LC; 50 μg/mL 
AgNPs; 50 μg/mL AgNPs + 10 μM DHA; 50 μg/mL AgNPs + 100 μM 
LC; 50 μg/mL AgNPs + 10 μM DHA + 100 μM LC (n = 4 in each 
group). Each bar in the figure denotes mean + SEM. Asterisks (*) 
indicate statistically significant differences in fold change by one-way 
ANOVA with Bonferroni’s multiple comparison post-hoc test. * p < 0.05, 
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2.3.2. Immunocytochemistry Analysis 
iPLA2 immunofluorescence labeling showed localization of 
iPLA2 protein in the cytoplasm of SH-SY5Y cells (Fig. 3.2.6). Six hours 
incubation of SH-SY5Y cells with 50 μg/mL AgNPs resulted in a 0.77-
fold (p < 0.001) statistically significant change in iPLA2 fluorescence 
intensity compared to vehicle control (Fig. 3.2.7). 
 
 
Fig. 3.2.6 Immunocytochemistry photos of iPLA2 protein expression in 
SH-SY5Y cells following six hours incubation with vehicle control and 
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Fig. 3.2.7 Fold change in iPLA2 fluorescence intensity in SH-SY5Y cells 
following six hours incubation with vehicle control and 50 μg/mL AgNPs 
(n = 4 in each group). Each bar in the figure denotes mean + SEM. 
Asterisks (*) indicate statistically significant differences in fold change 
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2.3.3. Trypan Blue Exclusion Cell Viability Assay Analysis 
Six hours incubation of SH-SY5Y cells resulted in cell 
viabilities of 98.3 %, 94.0 %, and 98.2 % for vehicle control, 50 μg/mL 
AgNPs-, and 91.3 μg/mL AuNPs-treated cells respectively (Fig. 3.2.8). 
No significant differences were observed between vehicle control and 
50 μg/mL AgNPs- and 91.3 μg/mL AuNPs-treated cells. 
 
 
Fig. 3.2.8 Cell viability of SH-SY5Y cells following six hours incubation 
with various treatment groups – vehicle control; 50 μg/mL AgNPs; 91.3 
μg/mL AuNPs (n = 4 in each group). Each bar in the figure denotes 
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2.3.4. Lipidomic Profiling Analysis 
Six hours incubation of SH-SY5Y cells with 50 μg/mL AgNPs 
resulted in significant differences in relative abundance of various 
phospholipid and lysophospholipid species compared to vehicle control 
(Table 3.2.1) – phosphatidylcholine (PC) (Fig. 3.2.9A & 3.2.9B), 
lysophosphatidylcholine (LysoPC) (Fig. 3.2.10A & 3.2.10B), 
phosphatidylethanolamine (PE) (Fig. 3.2.11A & 3.2.11B), and 
phosphatidylserine (PS) (Fig. 3.2.13). Significant increases in relative 
abundance of PC 30:0p, PC 30:0, PC 32:1e, PC 32:0e, PC 32:0p, PC 
32:2, PC 34:2e, PC 34:1e, PC 34:1p, PC 34:5, PC 34:4, PC 34:3, PC 
34:2, PC 36:2e, PC 36:6, PC 36:5, PC 36:3, PC 36:1, PC 36:0, PC 
38:4e, PC 38:4p, PC 38:7, PC 18:2/20:4, PC 38:2, PC 40:7e, PC 
40:5e, PC 40:6p, PC 40:8, PC 40:7, PC 40:6, PC 40:4, PE 34:1e, PE 
34:3, PE 34:2, PE 34:1, PE 35:2, PE 36:5e, PE 36:3, PE 36:2, PE 36:1, 
PE 36:0, PE 16:0p/20:4, PE 18:0p/18:1, PE 38:4, PE 38:3, PE 
16:0p/22:6, PE 16:0p/22:5, PE 40:7, PE 40:6, PE 40:5, PE 18:0p/22:6, 
PS 36:2, PS 36:1, PS 38:4, PS 38:3, PS 40:6, PS 40:5, LysoPC 18:0, 
LysoPC 24:0e, and LysoPC 26:0 lipid species were observed in 50 
μg/mL AgNPs-treated SH-SY5Y cells as compared to vehicle control. 
In contrast, PC 32:3 and PE 32:0 lipid species showed a significant 
reduction in relative abundance in 50 μg/mL AgNPs-treated cells as 
compared to vehicle control. No significant differences were observed 
in lysophosphatidylethanolamine (LysoPE) lipid species (Fig. 3.2.12). 
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Six hours incubation of SH-SY5Y cells with 50 μg/mL AgNPs 
also resulted in significant differences in relative abundance of 
sphingomyelin (SM) (Fig. 3.2.14) and ceramide (Cer) (Fig. 3.2.15) lipid 
species (Table 3.2.1). Significant increases in relative abundance of 
SM 31:1, SM 32:2, SM 32:1, SM 32:0, SM 33:1, SM 34:2, SM 34:1, SM 
34:0, SM 36:2, SM 36:1, SM 38:1, SM 39:1, SM 41:2, SM 34:1, SM 
42:1, Cer 16:0, Cer 18:0, Cer 20:0, Cer 22:0, Cer 24:1, and Cer 24:0 
lipid species were observed in 50 μg/mL AgNPs-treated SH-SY5Y cells 
as compared to vehicle control. 
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Table 3.2.1 Lipid species with significant changes in relative 




















PC 30:0p 2.18E-03 2.47E-04 2.46E-03 2.01E-04 0.047 
PC 30:0 2.79E-01 3.44E-03 2.90E-01 1.81E-02 0.039 
PC 32:1e 1.96E-02 1.28E-03 3.19E-02 1.87E-03 0.019 
PC 32:0e 4.41E-02 3.83E-03 5.57E-02 3.71E-03 0.014 
PC 32:0p 4.81E-03 2.56E-04 6.29E-03 7.80E-04 0.023 
PC 32:3 1.21E-02 1.48E-03 1.66E-02 1.19E-03 0.046 
PC 32:2 8.67E-02 9.66E-03 1.21E-01 8.80E-03 0.041 
PC 34:2e 1.12E-02 1.95E-04 1.80E-02 8.54E-04 0.032 
PC 34:1e 1.39E-01 9.13E-03 1.93E-01 1.07E-02 0.006 
PC 34:1p 1.07E-02 6.35E-04 1.65E-02 1.15E-03 0.002 
PC 34:5 3.18E-04 4.57E-05 4.08E-04 2.28E-05 0.009 
PC 34:4 9.45E-03 9.07E-04 1.17E-02 8.21E-04 0.035 
PC 34:3 5.79E-02 4.99E-03 7.75E-02 4.68E-03 0.019 
PC 34:2 2.89E-01 3.52E-03 3.23E-01 2.01E-02 0.023 
PC 36:2e 8.41E-03 7.85E-04 1.26E-02 7.03E-04 0.029 
PC 36:6 3.82E-03 3.32E-04 5.14E-03 2.78E-04 0.005 
PC 36:5 2.52E-02 5.82E-04 2.52E-02 1.41E-03 0.008 
PC 36:3 6.90E-02 4.34E-03 8.21E-02 4.43E-03 0.032 
PC 36:1 1.64E-01 3.66E-03 1.78E-01 1.03E-02 0.015 
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PC 36:0 2.44E-02 1.39E-03 2.82E-02 1.46E-03 0.022 
PC 38:4e 1.08E-02 9.65E-04 1.82E-02 1.82E-03 0.010 
PC 38:4p 1.38E-02 6.64E-04 1.90E-02 1.44E-03 0.010 
PC 38:7 6.47E-03 7.14E-04 8.55E-03 6.08E-04 0.001 
PC 
18:2/20:4 
4.71E-02 6.05E-04 5.28E-02 3.33E-03 0.003 
PC 38:2 9.36E-03 7.63E-04 1.19E-02 8.52E-04 0.020 
PC 40:7e 9.27E-03 7.26E-04 1.70E-02 1.17E-03 0.004 
PC 40:5e 6.34E-03 4.16E-04 8.83E-03 7.73E-04 0.016 
PC 40:6p 3.10E-03 3.57E-04 6.11E-03 7.06E-04 0.002 
PC 40:8 4.80E-03 3.17E-04 6.08E-03 3.60E-04 0.046 
PC 40:7 3.89E-02 2.11E-03 4.55E-02 2.48E-03 0.006 
PC 40:6 1.08E-02 6.44E-04 1.13E-02 5.61E-04 0.021 
PC 40:4 1.18E-02 1.25E-04 1.36E-02 8.89E-04 0.010 
PE 32:0 2.49E-02 1.16E-03 2.29E-02 6.33E-04 0.036 
PE 34:1e 1.11E-02 1.24E-03 2.89E-02 1.52E-03 0.014 
PE 34:3 3.27E-02 3.63E-03 4.88E-02 4.33E-03 0.029 
PE 34:2 1.40E-01 1.64E-02 1.89E-01 1.36E-02 0.027 
PE 34:1 3.71E-01 2.33E-02 4.50E-01 2.59E-02 0.028 
PE 35:2 2.28E-02 1.63E-03 2.98E-02 1.18E-03 0.020 
PE 36:5e 1.02E-02 5.41E-04 1.46E-02 1.50E-03 0.040 
PE 36:3 9.67E-02 9.62E-04 1.22E-01 4.93E-03 0.009 
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PE 36:2 4.47E-01 1.23E-02 5.36E-01 3.64E-02 0.002 
PE 36:1 6.99E-01 5.81E-02 7.97E-01 4.80E-02 0.027 
PE 36:0 8.64E-02 1.67E-03 9.50E-02 7.82E-03 0.014 
PE 
16:0p/20:4 
1.03E-02 5.17E-04 1.46E-02 1.50E-03 0.041 
PE 
18:0p/18:1 
3.60E-03 2.10E-04 4.35E-03 8.09E-04 0.009 
PE 38:4 1.10 1.42E-02 1.22 8.18E-02 0.003 
PE 38:3 4.76E-02 2.33E-03 6.45E-02 3.59E-03 0.003 
PE 
16:0p/22:6 
1.82E-02 3.26E-03 2.90E-02 3.06E-03 0.009 
PE 
16:0p/22:5 
5.31E-02 3.60E-03 9.69E-02 5.51E-03 0.011 
PE 40:7 1.34E-01 1.57E-02 1.76E-01 1.31E-02 0.017 
PE 40:6 2.60E-01 2.07E-02 3.44E-01 1.79E-02 0.019 
PE 40:5 3.24E-01 5.13E-03 3.47E-01 2.85E-02 0.004 
PE 
18:0p/22:6 
3.32E-02 4.34E-03 4.87E-02 3.32E-03 0.008 
PS 36:2 3.87 4.16E-01 5.67 4.55E-01 0.005 
PS 36:1 3.31E01 5.11E-01 4.54E01 3.35 0.017 
PS 38:4 2.42 1.10E-01 2.81 1.91E-01 0.010 
PS 38:3 3.08 2.14E-01 4.35 2.79E-01 0.006 
PS 40:6 9.84 7.14E-01 1.44E01 1.42 0.004 
PS 40:5 1.14E01 7.29E-01 1.44E01 1.21 0.009 
























LysoPC 18:0 3.31E-01 1.85E-02 4.82E-01 5.60E-02 0.030 
LysoPC 
24:0e 
1.62E-02 1.97E-03 2.63E-02 1.78E-03 0.012 
LysoPC 26:0 8.56E-02 4.52E-03 1.32E-01 1.88E-02 0.034 
SM 31:1 9.22E-03 3.28E-04 1.16E-02 1.05E-03 0.002 
SM 32:2 1.05E-02 9.72E-04 1.20E-02 1.03E-03 0.018 
SM 32:1 3.82E-01 3.40E-02 4.68E-01 3.38E-02 0.017 
SM 32:0 5.01E-02 3.87E-03 6.10E-02 2.83E-03 0.033 
SM 33:1 7.49E-01 9.25E-02 9.27E-01 8.43E-02 0.018 
SM 34:2 8.57E-01 7.28E-02 1.02 1.03E-03 0.021 
SM 34:1 9.17 7.51E-01 1.17E01 8.68E-01 0.018 
SM 34:0 4.91E-01 4.41E-02 5.95E-01 5.00E-02 0.014 
SM 36:2 4.10E-01 2.01E-02 5.05E-01 3.26E-02 0.024 
SM 36:1 6.68E-01 2.88E-02 8.25E-01 4.93E-02 0.003 
SM 38:1 2.18E-01 5.06E-03 2.41E-01 1.93E-02 0.008 
SM 39:1 4.69E-01 3.99E-02 7.25E-01 5.47E-02 0.009 
SM 41:2 4.14E-01 4.88E-02 6.95E-01 4.83E-02 0.011 
SM 41:1 1.39E-01 1.29E-02 2.02E-01 1.89E-02 0.006 
SM 42:1 1.33E-01 3.36E-04 1.34E-01 1.36E-02 0.001 
Cer 16:0 3.77E-01 2.55E-02 5.96E-01 2.70E-02 0.014 
Cer 18:0 9.36E-02 6.62E-03 1.40E-01 1.31E-03 0.013 
Cer 20:0 1.06E-02 1.65E-03 1.33E-02 7.52E-04 0.043 
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Cer 22:0 8.38E-02 2.19E-03 9.09E-02 5.08E-03 0.005 
Cer 24:1 3.76E-01 5.78E-03 4.11E-01 2.65E-02 0.002 
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Fig. 3.2.9 Relative abundance of phosphatidylcholine in SH-SY5Y cells 
following six hours incubation with vehicle control and 50 μg/mL 
AgNPs. Each bar in the figure denotes mean + SEM. Asterisks (*) 
indicate statistically significant differences in relative abundance by 
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Fig. 3.2.10 Relative abundance of lysophosphatidylcholine in SH-SY5Y 
cells following six hours incubation with vehicle control and 50 μg/mL 
AgNPs. Each bar in the figure denotes mean + SEM. Asterisks (*) 
indicate statistically significant differences in relative abundance by 
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Fig. 3.2.11 Relative abundance of phosphatidylethanolamine in SH-
SY5Y cells following six hours incubation with vehicle control and 50 
μg/mL AgNPs. Each bar in the figure denotes mean + SEM. Asterisks 
(*) indicate statistically significant differences in relative abundance by 
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Fig. 3.2.12 Relative abundance of lysophosphatidylethanolamine in 
SH-SY5Y cells following six hours incubation with vehicle control and 





























Fig. 3.2.13 Relative abundance of phosphatidylserine in SH-SY5Y cells 
following six hours incubation with vehicle control and 50 μg/mL 
AgNPs. Each bar in the figure denotes mean + SEM. Asterisks (*) 
indicate statistically significant differences in relative abundance by 
































Fig. 3.2.14 Relative abundance of sphingomyelin in SH-SY5Y cells 
following six hours incubation with vehicle control and 50 μg/mL 
AgNPs. Each bar in the figure denotes mean + SEM. Asterisks (*) 
indicate statistically significant differences in relative abundance by 




































































Fig. 3.2.15 Relative abundance of ceramide in SH-SY5Y cells following 
six hours incubation with vehicle control and 50 μg/mL AgNPs. Each 
bar in the figure denotes mean + SEM. Asterisks (*) indicate 
statistically significant differences in relative abundance by two-tailed 
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2.4. Discussion 
This chapter was conducted to examine the relationship 
between AgNPs and PLA2 enzymes, in particular cPLA2 and iPLA2, in 
SH-SY5Y human neuroblastoma cells. Since AgNPs have 
demonstrated inflammatory properties (Carlson et al., 2008, Cha et al., 
2008, Kim et al., 2010), I wanted to determine if AgNPs-induced toxicity 
is due to an induction of cPLA2, depression of iPLA2 expression and 
function, or both. sPLA2 activity has been heavily implicated in 
inflammatory conditions, however, it lacks specificity for the cleavage of 
fatty acids at the sn-2 position of glycerophospholipids (Burke and 
Dennis, 2009, Ong et al., 2015). As such, the present study focuses on 
cPLA2, which preferentially releases AA, a potent pro-inflammatory 
mediator (Sun et al., 2004, Dennis et al., 2011), and iPLA2, which 
preferentially releases DHA, a potent anti-inflammatory mediator 
(Green et al., 2008, Basselin et al., 2010). 
Interestingly, no significant changes in cPLA2 gene 
expression following incubation with AgNPs for up to six hours, while a 
significant reduction in iPLA2 gene expression from one to six hours 
was observed. This indicates that iPLA2 is more susceptible to AgNPs’ 
toxicity as compared to cPLA2, suggesting that AgNPs exerts its 
harmful effects through the inhibition of anti-inflammatory mechanisms 
instead of elevating pro-inflammatory pathways in SH-SY5Y cells. 
Moreover, iPLA2 protein expression decreased significantly after six 
hours exposure to AgNPs, as reflected by the significant drop in 
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fluorescence intensity using immunocytochemistry analysis. AgNPs 
exposure has also been reported to cause cell death in various cell 
lines (Braydich-Stolle et al., 2005, Carlson et al., 2008, Eom and Choi, 
2010). The observed decrease in iPLA2 expression could thus be 
potentially due to the loss of cells after exposure to AgNPs. However, 
six hours incubation of SH-SY5Y cells with AgNPs did not result in 
significant cell death. This implies that AgNPs exert its toxicity in SH-
SY5Y cells, in part by affecting iPLA2 expression. On the contrary, 
AuNPs showed a greater reduction in iPLA2 mRNA expression at one 
hour as compared to AgNPs-treated cells, although iPLA2 expression 
returned to similar to that of vehicle control after six hours exposure. 
The observed recovery suggests that SH-SY5Y cells are able to 
overcome the inhibitory effects of AuNPs on iPLA2 gene expression. 
This corroborates with other findings that AuNPs are generally safe, 
exhibiting lesser toxic effects as compared to AgNPs (Bar-Ilan et al., 
2009, Asharani et al., 2011). 
Additionally, it was shown in the previous chapter that acute 
exposure of SH-SY5Y cells to AgNPs resulted in mitochondrial 
dysfunction. The use of DHA and LC was able to rescue the harmful 
effects exerted by AgNPs in SH-SY5Y cells. However, co-treatment of 
DHA and/or LC with AgNPs did not result in significant changes in 
iPLA2 mRNA expression of SH-SY5Y cells, suggesting that 
supplementation of DHA and/or LC was unable to overcome changes 
observed in iPLA2 expression despite their ability to rescue harmful 
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effects exerted by AgNPs on mitochondria. As an integral 
housekeeping gene, iPLA2 plays many crucial roles in cells, including 
maintenance of mitochondrial integrity and its functions (Gadd et al., 
2006, Seleznev et al., 2006, Beck et al., 2011). This suggests that 
AgNPs affect iPLA2 expression upstream that of its effects exerted on 
human neuronal mitochondria, explaining for the inability of DHA and/or 
LC to alter iPLA2 expression. 
Alterations in activity of the iPLA2 enzyme following AgNPs 
treatment were investigated via lipidomic profiling. Since iPLA2 
preferentially releases DHA from phospholipids (Strokin et al., 2003, 
Green et al., 2008, Ong et al., 2015), it was postulated that AgNPs 
exposure to SH-SY5Y cells would result in lowered activity of the 
enzyme, i.e., less hydrolysis of glycerophospholipids to produce DHA 
and 2-lysophospholipids. Based on the molecular weights of PC, 
LysoPC, PE, and LysoPE lipid species, relative amount of released 
DHA by the action of iPLA2 enzyme can be determined. For example, 
PC 36:6 is hydrolyzed to produce LysoPC 14:0 and DHA, i.e. PC 36:6 
– LysoPC 14:0 = 22:6 (DHA). Similarly, PE 40:7 releases LysoPE 18:1 
and DHA. Lipidomic analysis revealed significant increases in PC and 
PE species and little to no significant changes in LysoPC and LysoPE 
species that are involved in the release of DHA, indicating decreased 
iPLA2 activity after six hours incubation with AgNPs. Decreased levels 
of PC and PE species such as PC 32:0, PC 36:5, and PE 32:0 were 
also detected. However, these are non-DHA-containing PC and PE 
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species as they have five or lesser double bonds in their fatty acid 
chains. Mitochondrial phospholipids are mainly made up of PC, PE, 
and cardiolipin lipid species (Zinser et al., 1991). Hence, alterations in 
these lipid species would have an effect on mitochondrial function, for 
instance, mitochondrial membrane integrity, permeability, and 
intracellular trafficking (Yorio and Frazier, 1990, Stenger et al., 2009, 
Sivaprakasam and Nachiappan, 2015). Taken together, the results 
suggest that AgNPs could exert its pro-inflammatory properties in SH-
SY5Y cells by modulating iPLA2 expression and function, in turn 
resulting in mitochondrial dysfunction. 
Lipidomic analysis also showed a significant increase in Cer 
lipid species following six hours incubation with AgNPs. Cer are lipid 
messengers that are involved with suppression of cell growth and 
induction of apoptosis (Obeid and Hannun, 1995). They can also work 
on mitochondria, causing the opening of the MPTP and release of 
cytochrome C, leading to mitochondrial dysfunction (Cutler et al., 
2004). iPLA2 is involved in the induction of ER stress that causes an 
increase in Cer levels (Lei et al., 2007). Additionally, the presence of 
ROS from AgNPs exposure could result in an increase in Cer levels 
(Cutler et al., 2004, Alessenko et al., 2005, Ichi et al., 2009). However, 
the resultant increase in Cer species is often due to the activation of 
sphingomyelinase, an enzyme that cleaves SM to produce Cer and 
phosphocholine (Alessenko et al., 2005, Lei et al., 2007). This 
contradicts the present study’s results as SM levels were found to 
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increase significantly following AgNPs treatment. Intriguingly, the 
addition of tumor necrosis factor, an inflammatory cytokine known to 
generate ROS in cells, increased both SM and Cer levels (Pekary and 
Hershman, 1998), indicating that ROS could affect phospholipid 
species in various ways. Additionally, it is possible that incubation with 
AgNPs resulted in increased SM levels so as to produce more Cer as 
SM are precursors of Cer. Six hours incubation with AgNPs also saw a 
significant increase in PS lipid species levels. Under apoptotic 
conditions, the translocation of PS from the inner to outer membrane of 
the plasma membrane act as a phagocytic “eat-me” signal (Verhoven 
et al., 1995). The increased PS lipid species could possibly be due to 
the preparation of apoptosis, in response to AgNPs exposure. 
Chapter 3 










ROLE OF OXIDATIVE STRESS IN SILVER 
NANOPARTICLES-INDUCED CALCIUM-
INDEPENDENT PHOSPHOLIPASE A2 CHANGES 
  
Chapter 3 
 Role of oxidative stress in AgNPs-induced iPLA2 changes	   	  
108 
3.1. Introduction 
In the previous chapters, it was established that acute 
exposure of AgNPs affects iPLA2 expression and function, in turn 
leading to mitochondrial dysfunction. AgNPs have been reported to 
cause cytotoxicity in cells due to generation of ROS, which react with 
cellular components like DNA and lipids, leading to mitochondrial 
dysfunction, DNA damage, and ultimately cell death (AshaRani et al., 
2009, Costa et al., 2010, Hwang et al., 2012, Kang et al., 2012, 
Mukherjee et al., 2012). iPLA2 has been reported to protect cells 
against oxidant-induced lipid peroxidation (Cummings et al., 2002, 
Kinsey et al., 2008, Eady et al., 2012), and the inhibition of iPLA2 
activity increases oxidant-induced cell death (Peterson et al., 2007). 
While iPLA2 plays a protective role against oxidative stress, the 
enzyme can also be inactivated by ROS due to the oxidation of iPLA2 
sulfhydryl groups (Cummings et al., 2004, Song et al., 2006). 
Decreased iPLA2 activity may thus lead to reduced cleavage, 
reacylation, and reinsertion of the peroxidized phospholipids into 
membranes, resulting in increased lipid peroxidation, and ultimately 
leading to cell death (Cummings et al., 2002, Cummings et al., 2004, 
Peterson et al., 2007). 
iPLA2 expression is potentially modulated by several 
regulatory factors at the promoter including Sp1 transcription factor 
(SP1), urocortin, and sterol regulatory element-binding proteins 
(SREBPs). iPLA2 contains several potential SP1 binding sites on its 
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promoter (Larsson Forsell et al., 1999), hence it could possibly regulate 
alterations in iPLA2 gene expression following exposure to AgNPs. 
However, SP1 is a general transcription factor that binds to GC-rich 
elements in DNA, and has been shown to affect multiple genes 
including cPLA2 (Tsou et al., 2008, Zhang et al., 2008). Similarly, 
urocortin regulates both cPLA2 and iPLA2 expression (Zhu et al., 2014). 
The results in chapter 2 indicate that AgNPs exposure in SH-SY5Y 
cells affects iPLA2 but not cPLA2 expression, suggesting that SP1 and 
urocortin are possibly not involved in the AgNPs-induced alterations of 
iPLA2 expression. 
On the other hand, iPLA2 promoter contains a sterol 
regulatory element (SRE) binding site for SREBPs that is not found on 
cPLA2 (Seashols et al., 2004, Chew and Ong, 2014). SREBPs are 
transcription factors that play an integral role in lipid homeostasis. In 
mammals, there are three isoforms, SREBP-1a, SREBP-1c, and 
SREBP-2 (Horton et al., 2003). SREBP-1a and SREBP-1c are 
alternatively spliced isoforms of the sterol regulatory element binding 
transcription factor 1 (SREBF1) gene found on human chromosome 
17p11.2, while SREBP-2 gene (SREBF2) is found on human 
chromosome 22q13 (Hua et al., 1995, Brown and Goldstein, 1997, 
Horton et al., 2002). SREBP-1a enhances transcription of all SREBP-
related genes, including genes involved in cholesterol and fatty acid 
synthesis, while SREBP-1c activates genes involved in fatty acid 
synthesis and SREBP-2 regulates expression of genes that play a role 
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in cholesterol synthesis and uptake. (Brown and Goldstein, 1997, 
Krycer and Brown, 2013). 
In this chapter, the role of oxidative stress in mediating 
AgNPs-induced decrease in iPLA2 expression and function was 
examined using antioxidants such as N-acetyl L-cysteine (NAC) and N-
tert-Butyl-α-phenylnitrone (PBN). The potential mechanism underlying 
the down-regulation of iPLA2 gene expression following acute exposure 
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3.2. Materials and Methods 
3.2.1. Cell Culture 
SH-SY5Y cells were cultured in complete growth medium, 
and grown in 100 mm dishes. SH-SY5Y cells were incubated under 
standard conditions of 37 °C and 5 % CO2, and regularly passaged 
with 0.25 % Trypsin-EDTA. At 70 % confluence, cells were used for 
treatments. 
 
3.2.2. Synthesis, Purification, and Characterization of AgNPs 
26 nm AgNPs were synthesized, purified, and characterized 
as described in chapter 1 (pages 40 – 43). 
 
3.2.3. Cell Treatment 
3.2.3.1. Treatment with NAC and AgNPs 
Four groups of SH-SY5Y cells were treated with the 
following reagents: (1) vehicle, water, (2) 1mM NAC (Sigma-Aldrich, St. 
Louis, MO, USA), (3) 50 μg/mL AgNPs, (4) 1 mM NAC and 50 μg/mL 
AgNPs. Cells were pre-treated with 1 mM NAC for one hour prior to 
addition of AgNPs for another six hours. PBS was used to wash the 
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3.2.3.2. Treatment with PBN and AgNPs 
Four groups of SH-SY5Y cells were treated with the 
following reagents: (1) vehicle, ethanol, (2) 10 μM PBN (Sigma-Aldrich, 
St. Louis, MO, USA), (3) 50 μg/mL AgNPs, (4) 10 μM PBN and 50 
μg/mL AgNPs. Cells were pre-treated with 10 μM PBN for one hour 
prior to addition of AgNPs for another six hours. PBS was used to wash 
the cells. SH-SY5Y cells were then harvested for further real-time RT-
PCR analyses. 
 
3.2.4. Real-time RT-PCR 
RNA of treated cells was extracted and real-time RT-PCR 
analyses were carried out as described in chapter 2 (page 72), using 
probes for human iPLA2 (Hs00185926_m1), SREBP-1 
(Hs01088691_m1), SREBP-2 (Hs01081784_m1), and ACTB (beta 
actin) (#4326315E) (Applied Biosystems®, Life Technologies, Carlsbad, 
CA, USA). 
 
3.2.5. Statistical analyses 
Mean and standard error of values were determined for 
each experimental group, and possible significant differences among 
various groups were analyzed using one-way ANOVA with Bonferroni’s 
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3.3. Results 
3.3.1. Real-time RT-PCR Analyses 
3.3.1.1. Effect of NAC and AgNPs Treatment on iPLA2 mRNA 
Expression 
Six hours incubation of SH-SY5Y cells with 50 μg/mL AgNPs 
resulted in a 0.43-fold (p < 0.001) statistically significant change in 
iPLA2 mRNA expression compared to vehicle control (Fig. 3.3.1). 1 mM 
NAC + 50 μg/mL AgNPs-treated cells also exhibited a 0.65-fold (p = 
0.005) statistically significant change in iPLA2 mRNA expression 
compared to vehicle control. Compared to 50 μg/mL AgNPs-treated 
SH-SY5Y cells, significant increase in iPLA2 mRNA expression was 
observed in cells treated with 1 mM NAC + 50 μg/mL AgNPs (p = 
0.023). Statistically significant reduction in iPLA2 mRNA expression 
was also observed in cells treated with 1 mM NAC compared to 1 mM 
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Fig. 3.3.1 Fold change in iPLA2 mRNA expression in SH-SY5Y cells 
following six hours incubation with various treatment groups – vehicle 
control; 1 mM NAC; 50 μg/mL AgNPs; 1 mM NAC + 50 μg/mL AgNPs 
(n = 4 in each group). Each bar in the figure denotes mean + SEM. 
Asterisks (*) indicate statistically significant differences in fold change 
by one-way ANOVA with Bonferroni’s multiple comparison post-hoc 



































 Role of oxidative stress in AgNPs-induced iPLA2 changes	   	  
115 
3.3.1.2. Effect of PBN and AgNPs Treatment on iPLA2 mRNA 
Expression 
Six hours incubation of SH-SY5Y cells with 50 μg/mL AgNPs 
resulted in a 0.48-fold (p = 0.001) statistically significant change in 
iPLA2 mRNA expression compared to vehicle control (Fig. 3.3.2). No 
significant difference was observed between 10 μM PBN + 50 μg/mL 
AgNPs-treated cells and vehicle control. Compared to 50 μg/mL 
AgNPs-treated SH-SY5Y cells, significant increase in iPLA2 mRNA 
expression was observed in cells treated with 10 μM PBN + 50 μg/mL 
AgNPs (p < 0.001). 
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Fig. 3.3.2 Fold change in iPLA2 mRNA expression in SH-SY5Y cells 
following six hours incubation with various treatment groups – vehicle 
control; 10 μM PBN; 50 μg/mL AgNPs; 10 μM PBN + 50 μg/mL AgNPs 
(n = 4 in each group). Each bar in the figure denotes mean + SEM. 
Asterisks (*) indicate statistically significant differences in fold change 
by one-way ANOVA with Bonferroni’s multiple comparison post-hoc 
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3.3.1.3. Effect of PBN and AgNPs Treatment on SREBP-1 mRNA 
Expression  
Six hours incubation of SH-SY5Y cells with 50 μg/mL AgNPs 
resulted in a 0.32-fold (p < 0.001) statistically significant change in 
SREBP-1 mRNA expression compared to vehicle control (Fig. 3.3.3). 
10 μM PBN-treated cells exhibited a 2.10-fold (p < 0.001) statistically 
significant increase in SREBP-1 mRNA expression compared to 
vehicle control. 10 μM PBN + 50 μg/mL AgNPs-treated cells exhibited 
a 0.58-fold (p < 0.001) statistically significant reduction in SREBP-1 
mRNA expression compared to vehicle control. Compared to 50 μg/mL 
AgNPs-treated SH-SY5Y cells, significant increase in SREBP-1 mRNA 
expression was observed in cells treated with 10 μM PBN + 50 μg/mL 
AgNPs (p < 0.001). Statistically significant reduction in SREBP-1 
mRNA expression was also observed in cells treated with 10 μM PBN 
compared to 10 μM PBN + 50 μg/mL AgNPs (p < 0.001). 
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Fig. 3.3.3 Fold change in SREBP-1 mRNA expression in SH-SY5Y 
cells following six hours incubation with various treatment groups – 
vehicle control; 10 μM PBN; 50 μg/mL AgNPs; 10 μM PBN + 50 μg/mL 
AgNPs (n = 4 in each group). Each bar in the figure denotes mean + 
SEM. Asterisks (*) indicate statistically significant differences in fold 
change by one-way ANOVA with Bonferroni’s multiple comparison 
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3.3.1.4. Effect of PBN and AgNPs Treatment on SREBP-2 mRNA 
Expression 
Six hours incubation of SH-SY5Y cells with 50 μg/mL AgNPs 
resulted in a 0.68-fold (p < 0.001) statistically significant change in 
SREBP-2 mRNA expression compared to vehicle control (Fig. 3.3.4). 
10 μM PBN-treated cells exhibited a 1.49-fold (p < 0.001) statistically 
significant increase in SREBP-2 mRNA expression compared to 
vehicle control. No significant difference was observed between 10 μM 
PBN + 50 μg/mL AgNPs-treated cells and vehicle control. Compared to 
50 μg/mL AgNPs-treated SH-SY5Y cells, significant increase in 
SREBP-2 mRNA expression was observed in cells treated with 10 μM 
PBN + 50 μg/mL AgNPs (p = 0.009). Statistically significant reduction 
in SREBP-2 mRNA expression was also observed in cells treated with 
10 μM PBN compared to 10 μM PBN + 50 μg/mL AgNPs (p < 0.001). 
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Fig. 3.3.4 Fold change in SREBP-2 mRNA expression in SH-SY5Y 
cells following six hours incubation with various treatment groups – 
vehicle control; 10 μM PBN; 50 μg/mL AgNPs; 10 μM PBN + 50 μg/mL 
AgNPs (n = 4 in each group). Each bar in the figure denotes mean + 
SEM. Asterisks (*) indicate statistically significant differences in fold 
change compared with vehicle control, by one-way ANOVA with 
Bonferroni’s multiple comparison post-hoc test. ** p < 0.01,  
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3.4. Discussion 
To determine if ROS and oxidative stress affects iPLA2 
expression, SH-SY5Y cells were pre-treated with the antioxidants NAC 
and PBN to observe for possible alterations in iPLA2 gene expression. 
NAC is a commonly used antioxidant with the ability to reduce oxidative 
stress and the downstream effects associated with oxidative stress 
(Kerksick and Willoughby, 2005). NAC works as an antioxidant in two 
ways. Firstly, it is a precursor of cysteine, which is the rate-limiting 
enzyme in the synthesis of glutathione, a crucial endogenous 
antioxidant. Under oxidative stress, glutathione levels are depleted and 
this can be reversed via NAC supplementation (Dodd et al., 2008). 
NAC is also an active scavenger for free radicals (Kerksick and 
Willoughby, 2005, Dodd et al., 2008). Similar to NAC, PBN scavenges 
for a wide range of free radicals (Sack et al., 1996). PBN is commonly 
known as a spin-trapping compound. It detoxifies free radicals by 
adding them to its carbon-nitrogen double bond resulting in a stable 
nitroxide product, which is subsequently metabolized and excreted in 
the urine (Sack et al., 1996). Antioxidant pre-treatment prevented the 
observed decrease in iPLA2 gene expression following AgNPs 
exposure, indicating that the AgNPs-induced down-regulation of iPLA2 
gene involves ROS. This corroborates with previous findings that acute 
exposure of AgNPs results in formation of ROS (Haase et al., 2012). 
Additionally, AgNPs-induced ROS affected iPLA2 gene expression 
through an unknown mechanism. 
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Oxidative stress can alter gene expression of various genes 
in multiple ways. Different ROS could produce different effects on 
various genes’ expression. Mackerness et al. (2001) found that H2O2 
derived from O2!- caused an up-regulation of PR-1 gene and down-
regulation of Lhcb gene, while O2!- resulted in an up-regulation of 
PDF1.2 gene. ROS could also alter gene expression by affecting cell 
signaling upstream of the gene. Wartenberg et al. (2001) determined 
that ROS down-regulated expression of Pgp gene via up-regulation of 
Erk1 and 2, and JNK. Additionally, ROS could affect transcription 
factors that have binding sites on the gene-of-interest’s promoter 
(McCullough et al., 2001). It would be interesting to determine the 
mechanism underlying the down-regulation of iPLA2 gene expression 
following six hours treatment with AgNPs. 
Since the iPLA2 promoter contains a SRE binding site for 
SREBPs that is not found on cPLA2 (Seashols et al., 2004, Lei et al., 
2010, Chew and Ong, 2014), it was decided to study the effects of 
oxidative stress on SREBP gene expression. As PBN pre-treatment 
resulted in a more significant change in iPLA2 expression, PBN pre-
treatment was used for subsequent investigations. AgNPs-treated cells 
showed significant reductions in both SREBP-1 and SREBP-2 
expression as compared to vehicle control, indicating that acute 
exposure of SH-SY5Y cells to AgNPs causes dysregulation of SREBP 
gene expression. Although it is not known how AgNPs result in 
aberrant modulation of SREBP expression, transcriptional activity of 
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SREBPs have been reported to be regulated in a variety of ways 
including proteolytic processing and recruitment of transcriptional 
cofactors (Xiaoping and Fajun, 2012). Furthermore, cells treated with 
PBN and AgNPs showed a significant increase in both SREBP-1 and 
SREBP-2 expression as compared to cells treated with only AgNPs, 
suggesting that SREBPs are affected by AgNPs-induced ROS 
formation. Reduction in SREBP expression could potentially limit 
amount of SREBP transcription factors binding to the SRE binding site 
on the iPLA2 promoter leading to lowered iPLA2 expression, as 
observed in the present study. 
Taken together, the present study’s results suggest that 
SREBPs are highly involved in AgNPs-induced down-regulation of 
iPLA2. Besides SREBPs, there may be other potential pathways 
involved. One possible mechanism is the AMPK signaling pathway, 
which has been shown to be activated by ROS in cultured cells (Hardie 
et al., 2012, Auciello et al., 2014). AMPK has also been demonstrated 
to inhibit SREBP expression and activity (Li et al., 2011, Liu et al., 
2015). Thus, it is plausible that AgNPs-induced ROS production could 
first activate AMPK, which suppresses SREBPs, in turn leading to the 
down-regulation of iPLA2. Nonetheless, additional work has to be done 
to validate these mechanisms.  
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In chapter 1, the acute effects of AgNPs in SH-SY5Y 
mitochondria were investigated. Mitochondrial membrane potential 
assay analysis showed that acute exposure of AgNPs to SH-SY5Y 
cells led to a drop in 590/535 ratio suggesting mitochondrial membrane 
damage. Additionally, ATP levels decreased in AgNPs-treated cells 
indicating possible damage to mitochondrial respiratory chain. As ATP 
levels decline, a corresponding rise in ADP levels is expected. 
Conversely, a decrease in ADP levels was detected. This could 
possibly be due to the action of AK decreasing the adenine nucleotide 
source and diminishing ADP and ATP stores. No significant cell death 
was detected after acute exposure to AgNPs. DHA and LC were then 
used to rescue AgNPs-induced mitochondrial dysfunction. Taken 
together, acute exposure of AgNPs to SH-SY5Y cells resulted in 
mitochondrial dysfunction and subsequently decreased ATP production 
without leading to cell death, which could be rescued by co-
supplementation with DHA and LC. 
In chapter 2, the relationship between AgNPs and PLA2 
enzymes, in particular cPLA2 and iPLA2, were investigated in SH-SY5Y 
cells. No significant changes in cPLA2 gene expression following 
incubation with AgNPs for up to six hours, while iPLA2 gene expression 
was significantly reduced from one to six hours. Immunocytochemistry 
analysis also revealed a significant decrease in iPLA2 protein 
expression following acute exposure to AgNPs. This observed 
reduction could possibly be due to loss of cells after AgNPs exposure, 
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however, no significant cell death was observed. Supplementation of 
DHA and/or LC was unable to overcome the iPLA2 expression changes 
despite their ability to rescue harmful effects exerted by AgNPs on 
mitochondria, indicating that AgNPs affect iPLA2 expression upstream 
that of its effects exerted on mitochondria. Alterations in iPLA2 activity 
following AgNPs treatment were investigated via lipidomic profiling. 
Lipidomic analysis revealed significant increases in PC and PE species 
and little to no significant changes in LysoPC and LysoPE species that 
are involved in DHA release, indicating decreased iPLA2 activity after 
acute exposure to AgNPs. Significant changes in Cer, SM, and PS lipid 
species were also detected. Taken together, AgNPs exert its 
inflammatory properties in SH-SY5Y cells by modulating iPLA2 
expression and function. 
In chapter 3, the effects of AgNPs-induced ROS and 
oxidative stress on iPLA2 expression were investigated, and the 
mechanism underlying changes observed was elucidated. Antioxidant 
pre-treatment prevented the observed decrease in iPLA2 gene 
expression following AgNPs exposure. Since the iPLA2 promoter 
contains a SRE binding site for SREBPs that is not found on cPLA2, 
effects of oxidative stress on SREBP expression were investigated. 
Cells treated with PBN and AgNPs showed a significant increase in 
both SREBP-1 and SREBP-2 expressions as compared to cells treated 
with only AgNPs. Taken together, the observed down-regulation of 
iPLA2 gene involves ROS production via acute exposure to AgNPs, 
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and the AgNPs-induced ROS formation affects SREBP expression. 
This could potentially reduce the amount of SREBP transcription 
factors binding to iPLA2 promoter, leading to reduced iPLA2 expression. 
In conclusion, the present study examined the acute effects 
of AgNPs in SH-SY5Y human neuroblastoma cells. Despite a short 
incubation period of up to six hours, AgNPs exposure led to ROS 
production in SH-SY5Y cells, causing reduced SREBP and iPLA2 
expression and function. This subsequently leads to mitochondrial 
dysfunction, which could be rescued through DHA and LC co-
supplementation (Fig. 4.1.1). The mechanism underlying AgNPs-
induced mitochondrial dysfunction in SH-SY5Y cells was thus 
elucidated in the present study. Besides SREBPs, there may be other 
potential pathways involved. One possible mechanism is the AMPK 
signaling pathway. Nonetheless, additional work has to be done to 
validate these mechanisms. Establishment of such mechanisms could 
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Fig. 4.1.1 Schematic flowchart of potential pathway and mechanism 
underlying acute effects of AgNPs in SH-SY5Y cells. 
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